Warenkorb Home Mein Konto Kundenservice

Markt Studien Datamonitor Pharma Gesundheit

TitelJahrPreis

CNS Market Access in China - Investment in mental health services offers growth opportunities for psychiatry players

Introduction / / China’s expanding and aging population makes the country an attractive market for manufacturers of CNS products.
2011 5.700,00$

CNS Market Access in India: Government investment into CNS services set to stimulate market growth

Introduction / / India's growing elderly population and expanding middle class population makes the country an attractive market
2011 5.700,00$

Epidemiology: Acute Coronary Syndrome - Now affecting primarily the oldest populations

Introduction / / Acute coronary syndrome is made up of three subtypes: STEMI, NSTEMI, and UA. With the exception of Japan, ACS oc
2011 3.800,00$

Epidemiology: Benign Prostatic Hyperplasia – Expected to continue growing as the male population ages

Introduction / / In 2010, Datamonitor estimates that there were 92.4 million prevalent cases of benign prostatic hyperplasia (BPH
2011 5.700,00$

Epidemiology: Bipolar Disorders – Population growth to mean more patients with bipolar disorders

Introduction / / In this analysis, Datamonitor estimates that there were a total of 8.5 million cases of bipolar disorders in 201
2011 5.700,00$

Epidemiology: HIV – Antiretrovirals prevail as patient population grows

Introduction / / The number of people living with HIV in the seven major markets (the US, Japan, France, Germany, Italy, Spain, a
2011 5.700,00$

Epidemiology: Osteopenia and Osteoporosis – On the rise as the aging population grows

Introduction / / The prevalence of hip fractures, a condition related to osteopenia and osteoporosis, increased during the latter
2011 5.700,00$

Epidemiology: Stroke – Aging global population leads to more incident cases of stroke

Introduction / / Due to an increasing number of aging adults in the world’s population, there will be an overall increase in the
2011 3.800,00$

E-Prescribing Strategies

Introduction / / As healthcare expenditure spirals ever higher, public and private healthcare payers are seeking to contain costs
2011 1.900,00$

Hot Topics in Type 2 Diabetes: Physician Perceptions of Incretin Mimetics and TZDs ¬– Physician survey provides insights into TZD, DPP-IV, and GLP-1 usage

Introduction / / Prescribing practices for the key branded non-insulin classes – TZDs, DPP-IV inhibitors, and GLP-1 agonists – va
2011 5.700,00$

Hot Topics: Obesity – Three Complete Response Letters and one Advisory Committee meeting

Introduction / / While two developers are pressing ahead with resubmission plans, a third is disputing US regulator handling and
2011 3.800,00$

Hot Topics: Obesity – The US FDA and cardiovascular risk analysis: the AdComm Cometh

Introduction / / Datamonitor proposes that the guidelines for developing obesity therapeutics are going to be overhauled in 2012,
2011 3.800,00$

Key Companies: Depression - Leading players must adapt to remain competitive

Introduction / / Companies seeking success in the depression market must react to the challenges posed by generic selective serot
2011 3.800,00$

Key Companies: Osteoporosis - Growing competition threatens leading franchises and drives innovation

Introduction / / The osteoporosis market is dominated by large pharmaceutical companies that can leverage their considerable fina
2011 3.800,00$

Merck & Co., Inc.: PharmaVitae Report

Introduction / / This analysis examines the historical and forecast performance for Merck & Co. in the prescription pharmaceutica
2011 5.700,00$

Mexico: Generics and Biosimilars Overview

Introduction / / Interchangeable generics (GIs; genéricos intercambiables) have traditionally held a small share of the Mexican m
2011 1.900,00$

Mexico: Healthcare System and Drug Regulatory Overview

Introduction / / While universal healthcare has yet to be accomplished in Mexico, the government believes it is achievable in 201
2011 1.900,00$

Mexico: Pharmaceutical Industry Infrastructure Overview

Introduction / / Mexico is one of the most attractive pharmaceutical markets in the Latin American region. It is increasingly ali
2011 1.900,00$

Oncology Market Access in China - Market bolstered by rising incidence and improved regulatory environment

Introduction / / The increasing adoption of Westernized lifestyles coupled with ongoing economic development is driving up the nu
2011 5.700,00$

Prescribing Influences: Allergic Rhinitis – Treatment tolerability remains a key differentiator

Introduction / / Many of the top challenges in allergic rhinitis are linked to the need for disease-modifying treatment, making t
2011 3.800,00$

Product Profiles: Obesity - Pipeline stalls as regulatory requirements escalate

Introduction / / The failure of obesity therapies to meet US FDA safety demands has resulted in a series of negative regulatory r
2011 11.400,00$

R&D Trends: Breast Cancer - Innovative approaches target key signaling pathways in breast tumors

Introduction / / The breast cancer pipeline contains 156 drugs, the majority of which (68%) are targeted therapies. VEGFR remain
2011 3.800,00$

R&D Trends: Neuropathic Pain - Extensive and diverse pipeline driven by high unmet need

Introduction / / Two key events occurred in the first half of 2011: Gralise (extended-release gabapentin; Depomed) obtained US Fo
2011 3.800,00$

R&D Trends: Non-Insulin Antidiabetics - What opportunities remain for the vast pipeline in the crowded diabetes market?

Introduction / / The non-insulins antidiabetic pipeline contains nearly 200 products. Although the current treatment algorithm is
2011 3.800,00$

R&D Trends: Rheumatoid Arthritis - Approaching an era of novel kinase inhibitors

Introduction / / Datamonitor has identified a total of 153 products in development for rheumatoid arthritis. There is considerabl
2011 3.800,00$

R&D Trends: Skin and soft tissue infections - MRSA threat drives R&D interest in an increasingly fragmented market

Introduction / / Despite the widespread use of vancomycin, the market for new drugs to treat SSTIs in hospitalized patients remai
2011 3.800,00$

Shire plc: PharmaVitae Report

Introduction / / This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sect
2011 5.700,00$

South Korea: Healthcare System and Drug Regulatory Overview

Introduction / / South Korea has high quality healthcare but comparatively low public financing. With high out-of-pocket costs, d
2011 1.900,00$

South Korea: Pharmaceutical Industry Infrastructure Overview

Introduction / / South Korea is among the top 10 new drug developers in the world. It has high quality standards and a skilled wo
2011 1.900,00$

Treatment Algorithms: Type 2 Diabetes – Novel classes drive fragmentation of treatment choices in type 2 diabetes

Introduction / / Datamonitor surveyed 199 primary care physicians and specialists across the seven major markets (the US, Japan,
2011 7.600,00$

Turkey: Generics and Biosimilars Overview

Introduction / / The Turkish generics market saw sales of $3.4bn in 2010, and has a high growth potential, driven by Turkish gene
2011 1.900,00$

Turkey: Healthcare System and Drug Regulatory Overview

Introduction / / Turkey continues to align its drug regulatory system with that of the EU. However, the country still has some wa
2011 1.900,00$

Turkey: Pharmaceutical Industry Infrastructure Overview

Introduction / / Leading multinational pharmaceutical companies often only have a small presence in the Turkish market, often thr
2011 1.900,00$

Dendreon Corporation: PharmaVitae Report

Introduction / / This analysis examines the historical and forecast performance for Dendreon in the prescription pharmaceutical s
2011 5.700,00$

Product Profiles: Systemic Lupus Erythematosus – Benlysta approval brings lessons and hope to market

Introduction / / Datamonitor surveyed 108 rheumatologists in the US in the wake of Benlysta’s approval, gauging current perceptio
2011 11.400,00$

Product Profiles: Allergic Rhinitis - Heavily genericized market sees areas of innovation

Introduction / / The allergic rhinitis market continues to see areas of innovation, as seen with the April 2011 FDA filing of Dym
2011 11.400,00$

R&D Trends: Attention-Deficit Hyperactivity Disorder - Growing pipeline indicates a trend towards adjunctive and adult therapy

Introduction / / Two drugs have progressed through the pipeline representing the first two products to receive US FDA approval fo
2011 3.800,00$

Product Profiles: Multiple Sclerosis - Gilenya raises bar for new market entrants

Introduction / / Beginning with the recent approval of Gilenya (Novartis; fingolimod), MS patients are experiencing the arrival o
2011 11.400,00$

Hot Topics in Type 2 Diabetes: Physician Perceptions of Insulin - Physician survey provides insights into insulin usage and needs

Introduction / / Insulin prescribing practices and physician perception of unmet needs vary widely among the seven major markets.
2011 5.700,00$

Epidemiology: Diabetes in Australia - Despite government efforts to promote healthy lifestyles, the number of cases of diabetes in Australia is set to soar

Introduction / / The number of people with type 2 diabetes will continue to increase, presenting a huge market for diabetic drugs
2011 5.700,00$

Product Profiles: Osteoporosis - Novel candidates offer the greatest potential

Introduction / / Despite major brands losing market exclusivity increasing cost competition, the osteoporosis market remains attr
2011 11.400,00$

R&D Trends: Prostate Cancer - Newly approved therapies shift treatment dynamics for castrate-resistant disease

Introduction / / The late-phase prostate cancer pipeline is dominated by targeted therapies, closely followed by immunotherapies.
2011 3.800,00$

Product Profiles: Depression - Next generation vies for second-line patients

Introduction / / Patents for the current market-leading depression brands are due to expire in the major markets between 2012 a
2011 11.400,00$

Prescribing Influences: Alzheimer's Disease - Alleviating symptoms remains the goal for prescribers

Introduction / / Datamonitor conducted a survey of neurologists to ascertain the perceived level of unmet need in Alzheimer’s d
2011 3.800,00$

Vertex Pharmaceuticals Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Vertex in the prescription pharmaceutical s
2011 5.700,00$

R&D Trends: Colorectal Cancer

Introduction / / The 113 drug colorectal cancer (CRC) pipeline is dominated by target therapies. VEGFR remains the leading targ
2011 1.900,00$

F. Hoffmann-La Roche Ltd: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical se
2011 5.700,00$

Key Companies: HIV - Companies co-operate and co-formulate to stay competitive in a tight HIV market

Introduction / / HIV across the seven major markets is largely dominated by two companies: Gilead Sciences and ViiV Healthcare.
2011 3.800,00$

Product Profiles: Autism Spectrum Disorders -Underserved market eagerly anticipates pipeline trial data

Introduction / / Over the past 6 years, three major events have impacted the autism spectrum disorders market. In 2006, Risperd
2011 11.400,00$

Pet Healthcare Market in Sweden to 2014

Introduction / / This databook provides key data and information on the pet healthcare market in Sweden. This report is a compreh
2011 495,00$

R&D Trends: Systemic Lupus Erythematosus - Benlysta’s FDA approval provides hope for disease treatment, future trial design, and other pipeline candidates

Introduction / / There remains considerable debate over the optimum efficacy measure and clinical trial design in SLE. While the
2011 3.800,00$

Pharmaceutical Key Trends 2011 Overview - Key strategic trends in the pharmaceutical industry

Introduction / / A number of factors have and will continue to impact pharmaceutical sales and profits going forward. As a result
2011 1.900,00$

Case Study: HIV - Better differential pricing strategies are needed to ensure access to HIV drugs

Introduction / / Although the majority of HIV drug developers already offer most of their antiretrovirals under differential pric
2011 1.900,00$

Epidemiology: Major Abdominal Surgery – A key risk factor for deep vein thrombosis and pulmonary embolism

Introduction / / In 2010, Datamonitor estimates that there were 7.4 million major abdominal surgeries in the seven major markets.
2011 5.700,00$

Case Study: Sepsis - Xigris’ disappointing performance creates a market opportunity for improved sepsis therapies

Introduction / / Sepsis has high mortality levels; however, only few therapeutic strategies exist. The Surviving Sepsis Campaign
2011 1.900,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Belgium

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Brazil

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Bulgaria

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Canada

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Chile

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in China

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Colombia

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Croatia

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Denmark

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Egypt

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Estonia

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Finland

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in France

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Germany

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Greece

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Hong Kong

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Hungary

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in India

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Ireland

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Israel

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Italy

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Japan

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Latvia

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Lithuania

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Malaysia

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Mexico

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Morocco

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in New Zealand

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Nigeria

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Norway

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Pakistan

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Peru

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Poland

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Portugal

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Republic of Korea

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Romania

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Russia

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Saudi Arabia

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Singapore

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Slovakia

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Slovenia

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in South Africa

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Spain

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Sweden

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Switzerland

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Taiwan

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in the Czech Republic

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in the Netherlands

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in the Philippines

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in the UK

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in the US

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Ukraine

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in United Arab Emirates

Introduction / Datamonitor's retail databooks are based on market value data for eight major sectors, 16 core retail distribution
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Uruguay

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Venezuela

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) Retail in Vietnam

Introduction / Datamonitor's retail databooks are based on key market value data for eight major sectors, 16 core retail distribut
2011 495,00$

Analgesics Market in Japan to 2014 (OTC Healthcare)

Introduction / / Analgesics Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level dat
2011 350,00$

Analgesics Market in Malaysia to 2014 (OTC Healthcare)

Introduction / / Analgesics Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level
2011 350,00$

Analgesics Market in Saudi Arabia to 2014 (OTC Healthcare)

Introduction / / Analgesics Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market and segment le
2011 350,00$

Analgesics Market in Sweden to 2014 (OTC Healthcare)

Introduction / / Analgesics Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level da
2011 350,00$

Analgesics Market in Switzerland to 2014 (OTC Healthcare)

Introduction / / Analgesics Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market and segment lev
2011 350,00$

Analgesics Market in Taiwan to 2014 (OTC Healthcare)

Introduction / / Analgesics Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level da
2011 350,00$

Analgesics Market in Thailand to 2014 (OTC Healthcare)

Introduction / / Analgesics Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level
2011 350,00$

Analgesics Market in the Philippines to 2014 (OTC Healthcare)

Introduction / / Analgesics Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for market and segment
2011 350,00$

Analgesics Market in the UK to 2014 (OTC Healthcare)

Introduction / / Analgesics Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level da
2011 350,00$

Analgesics Market in the US to 2014 (OTC Healthcare)

Introduction / / Analgesics Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level da
2011 350,00$

Analgesics Market in United Arab Emirates to 2014 (OTC Healthcare)

Introduction / / Analgesics Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for market and se
2011 350,00$

Analgesics Market in Uruguay to 2014 (OTC Healthcare)

Introduction / / Analgesics Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level d
2011 350,00$

OTC Healthcare in Canada to 2014

Introduction / This databook provides key data and information on the OTC healthcare market in Canada. This report is a comprehens
2011 495,00$

Other OTC Healthcare Products Market in Japan to 2014 (OTC Healthcare)

Introduction / / Other OTC Healthcare Products Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market an
2011 350,00$

Other OTC Healthcare Products Market in Malaysia to 2014 (OTC Healthcare)

Introduction / / Other OTC Healthcare Products Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market
2011 350,00$

Other OTC Healthcare Products Market in Saudi Arabia to 2014 (OTC Healthcare)

Introduction / / Other OTC Healthcare Products Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for ma
2011 350,00$

Other OTC Healthcare Products Market in Sweden to 2014 (OTC Healthcare)

Introduction / / Other OTC Healthcare Products Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market a
2011 350,00$

Other OTC Healthcare Products Market in Switzerland to 2014 (OTC Healthcare)

Introduction / / Other OTC Healthcare Products Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for mar
2011 350,00$

Other OTC Healthcare Products Market in Taiwan to 2014 (OTC Healthcare)

Introduction / / Other OTC Healthcare Products Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market a
2011 350,00$

Other OTC Healthcare Products Market in Thailand to 2014 (OTC Healthcare)

Introduction / / Other OTC Healthcare Products Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market
2011 350,00$

Other OTC Healthcare Products Market in the Philippines to 2014 (OTC Healthcare)

Introduction / / Other OTC Healthcare Products Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for
2011 350,00$

Other OTC Healthcare Products Market in the UK to 2014 (OTC Healthcare)

Introduction / / Other OTC Healthcare Products Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market a
2011 350,00$

Other OTC Healthcare Products Market in the US to 2014 (OTC Healthcare)

Introduction / / Other OTC Healthcare Products Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market a
2011 350,00$

Other OTC Healthcare Products Market in United Arab Emirates to 2014 (OTC Healthcare)

Introduction / / Other OTC Healthcare Products Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resourc
2011 350,00$

Other OTC Healthcare Products Market in Uruguay to 2014 (OTC Healthcare)

Introduction / / Other OTC Healthcare Products Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market
2011 350,00$

Topical OTC Medicines Market in Japan to 2014 (OTC Healthcare)

Introduction / / Topical OTC Medicines Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and segmen
2011 350,00$

Topical OTC Medicines Market in Malaysia to 2014 (OTC Healthcare)

Introduction / / Topical OTC Medicines Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and seg
2011 350,00$

Topical OTC Medicines Market in Saudi Arabia to 2014 (OTC Healthcare)

Introduction / / Topical OTC Medicines Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market and
2011 350,00$

Topical OTC Medicines Market in Sweden to 2014 (OTC Healthcare)

Introduction / / Topical OTC Medicines Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and segme
2011 350,00$

Topical OTC Medicines Market in Switzerland to 2014 (OTC Healthcare)

Introduction / / Topical OTC Medicines Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market and
2011 350,00$

Topical OTC Medicines Market in Taiwan to 2014 (OTC Healthcare)

Introduction / / Topical OTC Medicines Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and segme
2011 350,00$

Topical OTC Medicines Market in Thailand to 2014 (OTC Healthcare)

Introduction / / Topical OTC Medicines Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and seg
2011 350,00$

Topical OTC Medicines Market in the Philippines to 2014 (OTC Healthcare)

Introduction / / Topical OTC Medicines Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for market
2011 350,00$

Topical OTC Medicines Market in the UK to 2014 (OTC Healthcare)

Introduction / / Topical OTC Medicines Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and segme
2011 350,00$

Topical OTC Medicines Market in the US to 2014 (OTC Healthcare)

Introduction / / Topical OTC Medicines Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and segme
2011 350,00$

Topical OTC Medicines Market in United Arab Emirates to 2014 (OTC Healthcare)

Introduction / / Topical OTC Medicines Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for ma
2011 350,00$

Topical OTC Medicines Market in Uruguay to 2014 (OTC Healthcare)

Introduction / / Topical OTC Medicines Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and segm
2011 350,00$

Traditional Medicines Market in Japan to 2014 (OTC Healthcare)

Introduction / / Traditional Medicines Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and segmen
2011 350,00$

Traditional Medicines Market in Malaysia to 2014 (OTC Healthcare)

Introduction / / Traditional Medicines Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and seg
2011 350,00$

Traditional Medicines Market in Saudi Arabia to 2014 (OTC Healthcare)

Introduction / / Traditional Medicines Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market and
2011 350,00$

Traditional Medicines Market in Sweden to 2014 (OTC Healthcare)

Introduction / / Traditional Medicines Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and segme
2011 350,00$

Traditional Medicines Market in Switzerland to 2014 (OTC Healthcare)

Introduction / / Traditional Medicines Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market and
2011 350,00$

Traditional Medicines Market in Taiwan to 2014 (OTC Healthcare)

Introduction / / Traditional Medicines Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and segme
2011 350,00$

Traditional Medicines Market in Thailand to 2014 (OTC Healthcare)

Introduction / / Traditional Medicines Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and seg
2011 350,00$

Traditional Medicines Market in the Philippines to 2014 (OTC Healthcare)

Introduction / / Traditional Medicines Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for market
2011 350,00$

Traditional Medicines Market in the UK to 2014 (OTC Healthcare)

Introduction / / Traditional Medicines Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and segme
2011 350,00$

Traditional Medicines Market in the US to 2014 (OTC Healthcare)

Introduction / / Traditional Medicines Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and segme
2011 350,00$

Traditional Medicines Market in United Arab Emirates to 2014 (OTC Healthcare)

Introduction / / Traditional Medicines Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for ma
2011 350,00$

Traditional Medicines Market in Uruguay to 2014 (OTC Healthcare)

Introduction / / Traditional Medicines Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and segm
2011 350,00$

Pharmaceuticals Logistics Spending in Australia to 2014

Introduction / Pharmaceuticals Logistics Spending in Australia to 2014 assesses prospects for logistics in pharmaceutical industry
2011 695,00$

Pharmaceuticals Logistics Spending in Austria to 2014

Introduction / Pharmaceuticals Logistics Spending in Austria to 2014 assesses the prospects for logistics in pharmaceutical indust
2011 695,00$

Pharmaceuticals Logistics Spending in Belgium to 2014

Introduction / Pharmaceuticals Logistics Spending in Belgium to 2014 assesses the prospects for logistics in pharmaceutical indust
2011 695,00$

Pharmaceuticals Logistics Spending in Brazil to 2014

Introduction / Pharmaceuticals Logistics Spending in Brazil to 2014 assesses the prospects for logistics in pharmaceutical industr
2011 695,00$

Pharmaceuticals Logistics Spending in Canada to 2014

Introduction / Pharmaceuticals Logistics Spending in Canada to 2014 assesses the prospects for logistics in pharmaceutical industr
2011 695,00$

Pharmaceuticals Logistics Spending in China to 2014

Introduction / Pharmaceuticals Logistics Spending in China to 2014 assesses prospects for logistics in pharmaceutical industry. It
2011 695,00$

Pharmaceuticals Logistics Spending in France to 2014

Introduction / Pharmaceuticals Logistics Spending in France to 2014 assesses the prospects for logistics in pharmaceutical industr
2011 695,00$

Pharmaceuticals Logistics Spending in Germany to 2014

Introduction / Pharmaceuticals Logistics Spending in Germany to 2014 assesses the prospects for logistics in pharmaceutical indust
2011 695,00$

Pharmaceuticals Logistics Spending in Hungary to 2014

Introduction / Pharmaceuticals Logistics Spending in Hungary to 2014 assesses the prospects for logistics in pharmaceutical indust
2011 695,00$

Pharmaceuticals Logistics Spending in India to 2014

Introduction / Pharmaceuticals Logistics Spending in India to 2014 assesses prospects for logistics in pharmaceutical industry. It
2011 695,00$

Pharmaceuticals Logistics Spending in Italy to 2014

Introduction / Pharmaceuticals Logistics Spending in Italy to 2014 assesses the prospects for logistics in pharmaceutical industry
2011 695,00$

Pharmaceuticals Logistics Spending in Japan to 2014

Introduction / Pharmaceuticals Logistics Spending in Japan to 2014 assesses prospects for logistics in pharmaceutical industry. It
2011 695,00$

Pharmaceuticals Logistics Spending in Malaysia to 2014

Introduction / Pharmaceuticals Logistics Spending in Malaysia to 2014 assesses prospects for logistics in pharmaceutical industry.
2011 695,00$

Pharmaceuticals Logistics Spending in Mexico to 2014

Introduction / Pharmaceuticals Logistics Spending in Mexico to 2014 assesses the prospects for logistics in pharmaceutical industr
2011 695,00$

Pharmaceuticals Logistics Spending in Poland to 2014

Introduction / Pharmaceuticals Logistics Spending in Poland to 2014 assesses the prospects for logistics in pharmaceutical industr
2011 695,00$

Pharmaceuticals Logistics Spending in Portugal to 2014

Introduction / Pharmaceuticals Logistics Spending in Portugal to 2014 assesses the prospects for logistics in pharmaceutical indus
2011 695,00$

Pharmaceuticals Logistics Spending in Russia to 2014

Introduction / Pharmaceuticals Logistics Spending in Russia to 2014 assesses the prospects for logistics in pharmaceutical industr
2011 695,00$

Pharmaceuticals Logistics Spending in Singapore to 2014

Introduction / Pharmaceuticals Logistics Spending in Singapore to 2014 assesses prospects for logistics in pharmaceutical industry
2011 695,00$

Pharmaceuticals Logistics Spending in Spain to 2014

Introduction / Pharmaceuticals Logistics Spending in Spain to 2014 assesses the prospects for logistics in pharmaceutical industry
2011 695,00$

Pharmaceuticals Logistics Spending in Switzerland to 2014

Introduction / Pharmaceuticals Logistics Spending in Switzerland to 2014 assesses the prospects for logistics in pharmaceutical in
2011 695,00$

Pharmaceuticals Logistics Spending in the Netherlands to 2014

Introduction / Pharmaceuticals Logistics Spending in the Netherlands to 2014 assesses the prospects for logistics pharmaceutical i
2011 695,00$

Pharmaceuticals Logistics Spending in the UK to 2014

Introduction / Pharmaceuticals Logistics Spending in the UK to 2014 assesses the prospects for logistics in pharmaceutical industr
2011 695,00$

Pharmaceuticals Logistics Spending in the United Arab Emirates to 2014

Introduction / Pharmaceuticals Logistics Spending in United Arab Emirates to 2014. It provides information on total logistics (by
2011 695,00$

Pharmaceuticals Logistics Spending in the US to 2014

Introduction / Pharmaceuticals Logistics Spending in the US to 2014 assesses the prospects for logistics in pharmaceutical industr
2011 695,00$

Medicated Skin Products Market in Japan to 2014 (OTC Healthcare)

Introduction / / Medicated Skin Products Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and segm
2011 350,00$

Medicated Skin Products Market in Malaysia to 2014 (OTC Healthcare)

Introduction / / Medicated Skin Products Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and s
2011 350,00$

Medicated Skin Products Market in Saudi Arabia to 2014 (OTC Healthcare)

Introduction / / Medicated Skin Products Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market a
2011 350,00$

Medicated Skin Products Market in Sweden to 2014 (OTC Healthcare)

Introduction / / Medicated Skin Products Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and seg
2011 350,00$

Medicated Skin Products Market in Switzerland to 2014 (OTC Healthcare)

Introduction / / Medicated Skin Products Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market an
2011 350,00$

Medicated Skin Products Market in Taiwan to 2014 (OTC Healthcare)

Introduction / / Medicated Skin Products Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and seg
2011 350,00$

Medicated Skin Products Market in Thailand to 2014 (OTC Healthcare)

Introduction / / Medicated Skin Products Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and s
2011 350,00$

Medicated Skin Products Market in the Philippines to 2014 (OTC Healthcare)

Introduction / / Medicated Skin Products Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for marke
2011 350,00$

Medicated Skin Products Market in the UK to 2014 (OTC Healthcare)

Introduction / / Medicated Skin Products Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and seg
2011 350,00$

Medicated Skin Products Market in the US to 2014 (OTC Healthcare)

Introduction / / Medicated Skin Products Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and seg
2011 350,00$

Medicated Skin Products Market in United Arab Emirates to 2014 (OTC Healthcare)

Introduction / / Medicated Skin Products Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for
2011 350,00$

Medicated Skin Products Market in Uruguay to 2014 (OTC Healthcare)

Introduction / / Medicated Skin Products Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and se
2011 350,00$

Cough and Cold Preparations Market in Japan to 2014 (OTC Healthcare)

Introduction / / Cough and Cold Preparations Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and
2011 350,00$

Cough and Cold Preparations Market in Malaysia to 2014 (OTC Healthcare)

Introduction / / Cough and Cold Preparations Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market a
2011 350,00$

Cough and Cold Preparations Market in Saudi Arabia to 2014 (OTC Healthcare)

Introduction / / Cough and Cold Preparations Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for mark
2011 350,00$

Cough and Cold Preparations Market in Sweden to 2014 (OTC Healthcare)

Introduction / / Cough and Cold Preparations Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and
2011 350,00$

Cough and Cold Preparations Market in Switzerland to 2014 (OTC Healthcare)

Introduction / / Cough and Cold Preparations Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for marke
2011 350,00$

Cough and Cold Preparations Market in Taiwan to 2014 (OTC Healthcare)

Introduction / / Cough and Cold Preparations Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and
2011 350,00$

Cough and Cold Preparations Market in Thailand to 2014 (OTC Healthcare)

Introduction / / Cough and Cold Preparations Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market a
2011 350,00$

Cough and Cold Preparations Market in the Philippines to 2014 (OTC Healthcare)

Introduction / / Cough and Cold Preparations Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for m
2011 350,00$

Cough and Cold Preparations Market in the UK to 2014 (OTC Healthcare)

Introduction / / Cough and Cold Preparations Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and
2011 350,00$

Cough and Cold Preparations Market in the US to 2014 (OTC Healthcare)

Introduction / / Cough and Cold Preparations Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and
2011 350,00$

Cough and Cold Preparations Market in United Arab Emirates to 2014 (OTC Healthcare)

Introduction / / Cough and Cold Preparations Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource
2011 350,00$

Cough and Cold Preparations Market in Uruguay to 2014 (OTC Healthcare)

Introduction / / Cough and Cold Preparations Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market an
2011 350,00$

First Aid Kits Market in Japan to 2014 (OTC Healthcare)

Introduction / / First Aid Kits Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and segment level
2011 350,00$

First Aid Kits Market in Malaysia to 2014 (OTC Healthcare)

Introduction / / First Aid Kits Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and segment le
2011 350,00$

First Aid Kits Market in Saudi Arabia to 2014 (OTC Healthcare)

Introduction / / First Aid Kits Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market and segmen
2011 350,00$

First Aid Kits Market in Sweden to 2014 (OTC Healthcare)

Introduction / / First Aid Kits Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and segment leve
2011 350,00$

First Aid Kits Market in Switzerland to 2014 (OTC Healthcare)

Introduction / / First Aid Kits Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market and segment
2011 350,00$

First Aid Kits Market in Taiwan to 2014 (OTC Healthcare)

Introduction / / First Aid Kits Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and segment leve
2011 350,00$

First Aid Kits Market in Thailand to 2014 (OTC Healthcare)

Introduction / / First Aid Kits Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and segment le
2011 350,00$

First Aid Kits Market in the Philippines to 2014 (OTC Healthcare)

Introduction / / First Aid Kits Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for market and seg
2011 350,00$

First Aid Kits Market in the UK to 2014 (OTC Healthcare)

Introduction / / First Aid Kits Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and segment leve
2011 350,00$

First Aid Kits Market in the US to 2014 (OTC Healthcare)

Introduction / / First Aid Kits Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and segment leve
2011 350,00$

First Aid Kits Market in United Arab Emirates to 2014 (OTC Healthcare)

Introduction / / First Aid Kits Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for market an
2011 350,00$

First Aid Kits Market in Uruguay to 2014 (OTC Healthcare)

Introduction / / First Aid Kits Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and segment lev
2011 350,00$

Plasters and Bandages Market in Japan to 2014 (OTC Healthcare)

Introduction / / Plasters and Bandages Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and segmen
2011 350,00$

Plasters and Bandages Market in Malaysia to 2014 (OTC Healthcare)

Introduction / / Plasters and Bandages Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and seg
2011 350,00$

Plasters and Bandages Market in Saudi Arabia to 2014 (OTC Healthcare)

Introduction / / Plasters and Bandages Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market and
2011 350,00$

Plasters and Bandages Market in Sweden to 2014 (OTC Healthcare)

Introduction / / Plasters and Bandages Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and segme
2011 350,00$

Plasters and Bandages Market in Switzerland to 2014 (OTC Healthcare)

Introduction / / Plasters and Bandages Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market and
2011 350,00$

Plasters and Bandages Market in Taiwan to 2014 (OTC Healthcare)

Introduction / / Plasters and Bandages Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and segme
2011 350,00$

Plasters and Bandages Market in Thailand to 2014 (OTC Healthcare)

Introduction / / Plasters and Bandages Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and seg
2011 350,00$

Plasters and Bandages Market in the Philippines to 2014 (OTC Healthcare)

Introduction / / Plasters and Bandages Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for market
2011 350,00$

Plasters and Bandages Market in the UK to 2014 (OTC Healthcare)

Introduction / / Plasters and Bandages Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and segme
2011 350,00$

Plasters and Bandages Market in the US to 2014 (OTC Healthcare)

Introduction / / Plasters and Bandages Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and segme
2011 350,00$

Plasters and Bandages Market in United Arab Emirates to 2014 (OTC Healthcare)

Introduction / / Plasters and Bandages Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for ma
2011 350,00$

Plasters and Bandages Market in Uruguay to 2014 (OTC Healthcare)

Introduction / / Plasters and Bandages Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and segm
2011 350,00$

Indigestion Preparations Market in Japan to 2014 (OTC Healthcare)

Introduction / / Indigestion Preparations Market in Japan to 2014 (OTC Healthcare) is a comprehensive resource for market and seg
2011 350,00$

Indigestion Preparations Market in Malaysia to 2014 (OTC Healthcare)

Introduction / / Indigestion Preparations Market in Malaysia to 2014 (OTC Healthcare) is a comprehensive resource for market and
2011 350,00$

Indigestion Preparations Market in Saudi Arabia to 2014 (OTC Healthcare)

Introduction / / Indigestion Preparations Market in Saudi Arabia to 2014 (OTC Healthcare) is a comprehensive resource for market
2011 350,00$

Indigestion Preparations Market in Sweden to 2014 (OTC Healthcare)

Introduction / / Indigestion Preparations Market in Sweden to 2014 (OTC Healthcare) is a comprehensive resource for market and se
2011 350,00$

Indigestion Preparations Market in Switzerland to 2014 (OTC Healthcare)

Introduction / / Indigestion Preparations Market in Switzerland to 2014 (OTC Healthcare) is a comprehensive resource for market a
2011 350,00$

Indigestion Preparations Market in Taiwan to 2014 (OTC Healthcare)

Introduction / / Indigestion Preparations Market in Taiwan to 2014 (OTC Healthcare) is a comprehensive resource for market and se
2011 350,00$

Indigestion Preparations Market in Thailand to 2014 (OTC Healthcare)

Introduction / / Indigestion Preparations Market in Thailand to 2014 (OTC Healthcare) is a comprehensive resource for market and
2011 350,00$

Indigestion Preparations Market in the Philippines to 2014 (OTC Healthcare)

Introduction / / Indigestion Preparations Market in the Philippines to 2014 (OTC Healthcare) is a comprehensive resource for mark
2011 350,00$

Indigestion Preparations Market in the UK to 2014 (OTC Healthcare)

Introduction / / Indigestion Preparations Market in the UK to 2014 (OTC Healthcare) is a comprehensive resource for market and se
2011 350,00$

Indigestion Preparations Market in the US to 2014 (OTC Healthcare)

Introduction / / Indigestion Preparations Market in the US to 2014 (OTC Healthcare) is a comprehensive resource for market and se
2011 350,00$

Indigestion Preparations Market in United Arab Emirates to 2014 (OTC Healthcare)

Introduction / / Indigestion Preparations Market in United Arab Emirates to 2014 (OTC Healthcare) is a comprehensive resource for
2011 350,00$

Indigestion Preparations Market in Uruguay to 2014 (OTC Healthcare)

Introduction / / Indigestion Preparations Market in Uruguay to 2014 (OTC Healthcare) is a comprehensive resource for market and s
2011 350,00$

Healthcare Equipment and Disposables Logistics Spending in Australia to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Australia to 2014 assesses the prospects for logistics.
2011 695,00$

Healthcare Logistics Spending in Australia to 2014

Introduction / Healthcare Logistics Spending in Australia to 2014 assesses the prospects for logistics in healthcare industry. It
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Austria to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Austria to 2014 assesses the prospects for logistics. It
2011 695,00$

Healthcare Logistics Spending in Austria to 2014

Introduction / Healthcare Logistics Spending in Austria to 2014 assesses the prospects for logistics in healthcare industry. It pr
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Belgium to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Belgium to 2014 assesses the prospects for logistics. It
2011 695,00$

Healthcare Logistics Spending in Belgium to 2014

Introduction / Healthcare Logistics Spending in Belgium to 2014 assesses the prospects for logistics in healthcare industry. It pr
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Brazil to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Brazil to 2014 assesses the prospects for logistics. It
2011 695,00$

Healthcare Logistics Spending in Brazil to 2014

Introduction / Healthcare Logistics Spending in Brazil to 2014 assesses the prospects for logistics in healthcare industry. It pro
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Canada to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Canada to 2014 assesses the prospects for logistics. It
2011 695,00$

Healthcare Logistics Spending in Canada to 2014

Introduction / Healthcare Logistics Spending in Canada to 2014 assesses the prospects for logistics in healthcare industry. It pro
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in China to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in China to 2014 assesses the prospects for logistics. It p
2011 695,00$

Healthcare Logistics Spending in China to 2014

Introduction / Healthcare Logistics Spending in China to 2014 assesses the prospects for logistics in healthcare industry. It prov
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in France to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in France to 2014 assesses the prospects for logistics. It
2011 695,00$

Healthcare Logistics Spending in France to 2014

Introduction / Healthcare Logistics Spending in France to 2014 assesses the prospects for logistics in healthcare industry. It pro
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Germany to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Germany to 2014 assesses the prospects for logistics. It
2011 695,00$

Healthcare Logistics Spending in Germany to 2014

Introduction / Healthcare Logistics Spending in Germany to 2014 assesses the prospects for logistics in healthcare industry. It pr
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Hungary to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Hungary to 2014 assesses the prospects for logistics. It
2011 695,00$

Healthcare Logistics Spending in Hungary to 2014

Introduction / Healthcare Logistics Spending in Hungary to 2014 assesses the prospects for logistics in healthcare industry. It pr
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in India to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in India to 2014 assesses the prospects for logistics. It p
2011 695,00$

Healthcare Logistics Spending in India to 2014

Introduction / Healthcare Logistics Spending in India to 2014 assesses the prospects for logistics in healthcare industry. It prov
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Italy to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Italy to 2014 assesses the prospects for logistics. It p
2011 695,00$

Healthcare Logistics Spending in Italy to 2014

Introduction / Healthcare Logistics Spending in Italy to 2014 assesses the prospects for logistics in healthcare industry. It prov
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Japan to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Japan to 2014 assesses the prospects for logistics. It p
2011 695,00$

Healthcare Logistics Spending in Japan to 2014

Introduction / Healthcare Logistics Spending in Japan to 2014 assesses the prospects for logistics in healthcare industry. It prov
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Malaysia to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Malaysia to 2014 assesses the prospects for logistics. I
2011 695,00$

Healthcare Logistics Spending in Malaysia to 2014

Introduction / Healthcare Logistics Spending in Malaysia to 2014 assesses the prospects for logistics in healthcare industry. It p
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Mexico to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Mexico to 2014 assesses the prospects for logistics. It
2011 695,00$

Healthcare Logistics Spending in Mexico to 2014

Introduction / Healthcare Logistics Spending in Mexico to 2014 assesses the prospects for logistics in healthcare industry. It pro
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Poland to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Poland to 2014 assesses the prospects for logistics. It
2011 695,00$

Healthcare Logistics Spending in Poland to 2014

Introduction / Healthcare Logistics Spending in Poland to 2014 assesses the prospects for logistics in healthcare industry. It pro
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Portugal to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Portugal to 2014 assesses the prospects for logistics.
2011 695,00$

Healthcare Logistics Spending in Portugal to 2014

Introduction / Healthcare Logistics Spending in Portugal to 2014 assesses the prospects for logistics in healthcare industry. It
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Russia to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Russia to 2014 assesses the prospects for logistics. It
2011 695,00$

Healthcare Logistics Spending in Russia to 2014

Introduction / Healthcare Logistics Spending in Russia to 2014 assesses the prospects for logistics in healthcare industry. It pro
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Singapore to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Singapore to 2014 assesses the prospects for logistics.I
2011 695,00$

Healthcare Logistics Spending in Singapore to 2014

Introduction / Healthcare Logistics Spending in Singapore to 2014 assesses the prospects for logistics in healthcare industry. It
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Spain to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Spain to 2014 assesses the prospects for logistics. It p
2011 695,00$

Healthcare Logistics Spending in Spain to 2014

Introduction / Healthcare Logistics Spending in Spain to 2014 assesses the prospects for logistics in healthcare industry. It prov
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in Switzerland to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in Switzerland to 2014 assesses the prospects for logistics
2011 695,00$

Healthcare Logistics Spending in Switzerland to 2014

Introduction / Healthcare Logistics Spending in Switzerland to 2014 assesses the prospects for logistics in healthcare industry. I
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in the Netherlands to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in the Netherlands to 2014 assesses the prospects for logi
2011 695,00$

Healthcare Logistics Spending in the Netherlands to 2014

Introduction / Healthcare Logistics Spending in the Netherlands to 2014 assesses the prospects for logistics in healthcare industr
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in the UK to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in the UK to 2014 assesses the prospects for logistics. It
2011 695,00$

Healthcare Logistics Spending in the UK to 2014

Introduction / Healthcare Logistics Spending in UK to 2014 assesses the prospects for logistics in healthcare industry. It provide
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in the US to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in the US to 2014 assesses the prospects for logistics. It
2011 695,00$

Healthcare Logistics Spending in the US to 2014

Introduction / Healthcare Logistics Spending in the US to 2014 assesses the prospects for logistics in healthcare industry. It pro
2011 695,00$

Healthcare Equipment and Disposables Logistics Spending in United Arab Emirates to 2014

Introduction / Healthcare Equipment and Disposables Logistics Spending in United Arab Emirates to 2014 .It provides information on
2011 695,00$

Healthcare Logistics Spending in UAE to 2014

Introduction / Healthcare Logistics Spending in UAE to 2014 assesses the prospects for logistics in healthcare industry. It provid
2011 695,00$

R&D Trends: Insulin Antidiabetics - The future is analogs

Introduction / / The insulin antidiabetic pipeline can be split between small manufacturers, often targeting reformulations of ex
2011 3.800,00$

Pharmaceutical Key Trends 2011 – Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions

Introduction / / The combined generics market size is valued at approximately $77bn in the US, Japan, the five major EU markets (
2011 3.800,00$

Pharmaceutical Key Trends 2011 – Socio-Demographic and Economic Overview : Rising healthcare costs coupled with the economic downturn continue to shape the healthcare landscape

Introduction / / Aging populations, the growing prevalence of chronic disease, greater use of expensive treatments, and expanding
2011 1.900,00$

R&D Trends: Depression - Pipeline characterized by its depth and diversity

Introduction / / Several drugs have progressed through the pipeline for depression in recent years, including Pristiq (desvenlafa
2011 3.800,00$

R&D Trends: Autism Spectrum Disorders - Unknown etiology and low industry interest hinders pipeline progression

Introduction / / Since 2006, two drugs have gained FDA approval for the symptomatic treatment of irritability in autism spectrum
2011 3.800,00$

R&D Trends: Sepsis - Improvements in clinical trial design and advances in biomarker research hold the key to a tailored approach to sepsis therapy

Introduction / / Despite Eli Lilly’s Xigris being the only licensed therapeutic, the sepsis market remains commercially attractiv
2011 3.800,00$

Health Concerns & Alcoholic Beverage Preferences: Implications for NPD

Introduction / / As health has become a more important issue for consumers generally, the influence it has had on alcoholic bever
2011 3.450,00$

Epidemiology: Major Orthopedic Surgery – On the rise as the global elderly population continues to grow

Introduction / / In 2010, Datamonitor estimates that there were 5.3 million orthopedic surgeries in the seven major markets. Due
2011 5.700,00$

R&D Trends: Obesity - 2006–2011: obesity’s lean years

Introduction / / Modest efficacy results and lingering safety concerns have meant that developers of obesity drugs have failed to
2011 3.800,00$

AstraZeneca: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for AstraZeneca in the prescription pharmaceutica
2011 5.700,00$

GlaxoSmithKline plc: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for GlaxoSmithKline in the prescription pharmaceu
2011 5.700,00$

Genzyme Corporation

Introduction / / This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical se
2011 5.700,00$

Abbott Laboratories: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sec
2011 5.700,00$

Mitsubishi Tanabe Pharma Corp.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the prescription pharmac
2011 5.700,00$

R&D Trends: Multiple Sclerosis - Progressive subtypes remain underserved in expansive pipeline

Introduction / / In recent years, there has been a paradigm shift in the pipeline for new MS therapies, with a growing number of
2011 3.800,00$

UK Healthcare Cash Plans 2011

Introduction / / This brief provides a detailed study of the UK healthcare cash plan market, with information on market size and
2011 2.795,00$

Case Study: Autism Spectrum Disorders - Public awareness and physician detailing will drive market growth

Introduction / / To date, only two products have gained approval for the treatment of ASDs; Risperdal (risperidone; Johnson & Joh
2011 1.900,00$

Epidemiology: Diabetes in India - a country faced with a mammoth diabetes epidemic

Introduction / / The World Health Organization (WHO) estimates that worldwide, there are currently 220 million people living with
2010 7.600,00$

Shionogi & Co., Ltd: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Shionogi in the prescription pharmaceutical s
2011 5.700,00$

Epidemiology: Insomnia

Introduction / / In this analysis, Datamonitor estimates that there were a total of 53 million cases of insomnia in 2010 in the s
2011 5.700,00$

Bristol-Myers Squibb Co.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Bristol-Myers Squibb in the prescription phar
2011 5.700,00$

Epidemiology: Allergic Rhinitis - Allergic rhinitis is highly prevalent yet significantly under-diagnosed

Introduction / / By 2020, approximately 157 million adults and 31 million children will be living with allergic rhinitis across t
2011 3.800,00$

Commercial Insight: Osteoporosis – Market players maximize revenue growth before the next challenging phase

Analysis of global osteoporosis prescriptions from 2005–09, split by geographical region (including emerging markets), drug class,
2010 15.200,00$

Pipeline Insight: Osteoporosis - Bone building drugs become the heart of the pipeline

Patient potential analysis across the seven major markets and BRIC nations (Brazil, Russia, India, and China).Review of the key cl
2010 11.400,00$

Stakeholder Opinions: Hemophilia - The harsh reality of commercialising a great research opportunity?

Analysis of global osteoporosis prescriptions from 2005–09, split by geographical region (including emerging markets), drug class,
2010 3.800,00$

Stakeholder Insight: Hepatitis B & C in Asia - China, South Korea, Taiwan and Turkey

Current epidemiology of HBV and HCV, including prevalence, diagnosis and treatment rates as well as patient split by line and choi
2010 15.200,00$

Pipeline and Commercial Insight: Testosterone Replacement Therapy - Topical formulations drive market growth

Patient potential analysis across the seven major marketsReview of the key needs supported by key opinion leadersCurrent and futur
2010 15.200,00$

Pipeline and Commercial Insight: Hormonal Replacement Therapy for Menopausal Symptoms - Safety fears continue to haunt the market

Patient potential analysis across the seven major marketsReview of the key needs supported by key opinion leaders from the US and
2010 15.200,00$

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity

Snapshot of the current rheumatoid arthritis market based on a survey of 183 rheumatologists, supported with views from key opinio
2010 15.200,00$

Pipeline and Commercial Insight: Pneumococcal and Meningococcal Vaccines

Introduction / / Over the next decade, Pfizer’s Prevnar 13 is set to dominate the pneumococcal vaccine market with sales that cou
2010 15.200,00$

Les Laboratoires Servier: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical se
2010 5.700,00$

King Pharmaceuticals Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for King in the prescription pharmaceutical secto
2010 5.700,00$

Merck & Co., Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Merck & Co. in the prescription pharmaceutica
2010 5.700,00$

Sanofi-Aventis: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Sanofi-Aventis in the prescription pharmaceut
2010 5.700,00$

Novartis AG: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Novartis in the prescription pharmaceutical s
2010 5.700,00$

GlaxoSmithKline plc: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for GlaxoSmithKline in the prescription pharmaceu
2010 5.700,00$

Pfizer Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Pfizer in the prescription pharmaceutical sec
2010 5.700,00$

Australia Pharmaceutical Market Overview - Reforms and continued price cuts will change the healthcare landscape

Introduction / / The prescription pharmaceutical market in Australia was valued at $9.1 billion in 2009. Key growth drivers inclu
2010 7.600,00$

Commercial Insight: Cytotoxic Therapies - Drug launches in rare indications to offset the decline in cytotoxic sales

Introduction / / Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%. Several blockbuster produ
2010 15.200,00$

Russia Pharmaceutical Market Overview Pharma companies target Russia despite the challenges it presents

Introduction / / The Russian pharmaceutical market generated $10.1 billion in sales in 2009, growing by 14.5% between 2008 and 20
2010 7.600,00$

China Pharmaceutical Market Overview

Introduction / The Chinese hospital prescription pharma market generated sales of $22.9 billion in 2009, with an annual growth rat
2010 7.600,00$

Allergan Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Allergan in the prescription pharmaceutical s
2010 5.700,00$

Chugai Pharmaceutical Co., Ltd: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sec
2010 5.700,00$

Novo Nordisk A/S: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Novo Nordisk in the prescription pharmaceutic
2010 5.700,00$

Teva Pharma. Industries Ltd: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Teva in the prescription pharmaceutical secto
2010 5.700,00$

CSL Limited: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for CSL in the prescription pharmaceutical sector
2010 5.700,00$

Shire plc: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sect
2010 5.700,00$

Mylan Inc.: PharmaVitae Profile

Introduction / / The analysis examines the historical and forecast performance for Mylan in the generic prescription pharmaceutic
2010 5.700,00$

Boehringer Ingelheim GmbH: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Boehringer Ingelheim in the prescription phar
2010 5.700,00$

UCB S.A.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector
2010 5.700,00$

Forest Laboratories Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Forest in the prescription pharmaceutical sec
2010 5.700,00$

Apotex Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Apotex in the prescription pharmaceutical sec
2010 5.700,00$

AstraZeneca plc: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for AstraZeneca in the prescription pharmaceutica
2010 5.700,00$

Celgene Corporation: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Celgene in the prescription pharmaceutical se
2010 5.700,00$

Pipeline Insight: Cancer Overview Malignant Melanoma, Neuroendocrine Tumors and Thyroid Cancer - New drug approvals likely after decades of little progress

Introduction / / There are currently 100 drugs in the pipeline for melanoma, thyroid cancer and neuroendocrine tumors with 16 in
2010 11.400,00$

Johnson & Johnson: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Johnson & Johnson in the prescription pharmac
2010 5.700,00$

H. Lundbeck A/S: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Lundbeck in the prescription pharmaceutical s
2010 5.700,00$

Cephalon Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Cephalon in the prescription pharmaceutical s
2010 11.400,00$

Warner-Chilcott Plc: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Warner Chilcott in the prescription pharmaceu
2010 5.700,00$

Watson Pharmaceuticals Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Watson in the prescription pharmaceutical sec
2010 5.700,00$

Daiichi Sankyo Co., Ltd: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Daiichi Sankyo in the prescription pharmaceut
2010 5.700,00$

Baxter International Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Baxter in the prescription pharmaceutical sec
2010 5.700,00$

Otsuka Pharmaceutical Co., Ltd: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Otsuka in the prescription pharmaceutical sec
2010 5.700,00$

Alcon Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Alcon in the prescription pharmaceutical sect
2010 5.700,00$

France Pharmaceutical Market Overview – Austerity measures will impact pharmaceutical market growth

Introduction / / The prescription pharma market in France was valued at $38.8bn in sales in 2009, having by 3.1% (CAGR; 2005–09
2010 11.400,00$

India Pharmaceutical Market Overview Growing economic wealth fuels pharma market growth, but generics dominate

The prescription pharmaceutical market in India generated $7.1 billion in sales in 2009, with an annual growth rate of 18.1% betwe
2010 7.600,00$

Healthcare Regulatory Update: The United Arab Emirates

Introduction / / The fragmented nature of the healthcare systems in the United Arab Emirates remains despite the implementation o
2010 3.800,00$

Pharmaceutical Key Trends 2010

Introduction / / Pharma faces a number of key resistors to growth including the impending 2011 patent cliff which is set to erode
2010 11.400,00$

Stakeholder Opinions: Sexual Dysfunction - The quest for the new Viagra continues

Overview of erectile dysfunction, premature ejaculation and female sexual dysfunction disorders including epidemiology and key unm
2010 7.600,00$

Pharmaceutical Licensing Overview

Overview of Big Pharma's current and anticipated future reliance on externally sourced productsOverview of drivers and resistors o
2010 15.200,00$

Stakeholder Opinions: Respiratory viral infections - Respiratory syncytial virus, parainfluenza virus and human metapneumovirus as promising new targets

Analysis of the market for respiratory viral infections across the US, Japan, France, Italy, Germany, Spain and the UKStrategic an
2010 3.800,00$

Pipeline Insight: Inflammatory Bowel Disease - Varied drug targets to broaden future therapy options

Segmentation and analysis of products across all stages of the IBD pipeline with in-depth discussion of key Phase II and III pipel
2010 11.400,00$

Pharmaceutical M&A in the Asia-Pacific Region – India and China drive regional activity but Japan still dominates high value transactions

Introduction / / Expanding healthcare coverage in emerging Asia-Pacific markets, rapid economic growth and burgeoning middle clas
2010 7.600,00$

Infectious Diseases Vaccine Market Overview

Introduction / / Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Phar
2010 15.200,00$

Pharmaceutical Company Outlook to 2015

Introduction / / Historical and forecast analysis of the PharmaVitae Universe from 2003 through to 2015. Strategic dynamics wit
2010 7.600,00$

Pharmaceutical Licensing and Alliances in the Asia-Pacific Region – Pharma enhances its focus on APAC markets

Introduction / / While the Japanese market with its increasingly globally-minded pharma companies still dominates deal activities
2010 7.600,00$

Stakeholder Insight: COPD in Emerging Markets (Brazil, India, China, US) - Key differences in treatment despite standardized guidelines

Introduction / / While general COPD treatment patterns are consistent across the emerging markets compared to the US, some key di
2010 15.200,00$

Stakeholder Insight: Epilepsy - Neurologists remain loyal to brands in genericized market

Introduction / / The epilepsy market has become increasingly competitive following the launch of Vimpat (lacosamide; UCB) in the
2010 15.200,00$

Stakeholder Opinions: Hepatocellular cancer

Introduction / Despite the approval of Nexavar (sorafenib; Onyx pharmaceuticals/Bayer), patient outcomes remain poor. The large pa
2010 3.800,00$

Stakeholder Opinions: Tropical Diseases - Dengue, Japanese encephalitis and West Nile virus – Increasing attention for neglected diseases

Introduction / Dengue, Japanese encephalitis and West Nile virus are major causes of disease worldwide. Dual market pricing strate
2010 3.800,00$

Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development

Introduction / The treatment of cancer has seen a dramatic shift with the addition of molecular targeted therapies. The mixed and
2011 1.900,00$

Eisai Co., Ltd: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Eisai in the prescription pharmaceutical sect
2011 5.700,00$

Pharmaceutical Key Trends 2011 – Biosimilar Market Overview

Introduction / / In 2009, the combined biosimilars market size for the US and five major European markets was $150m. With more th
2011 3.800,00$

Pipeline Insight: Antibacterials

Introduction / / The antibacterial pipeline is robust with regards to new drugs for the treatment of Gram-positive pathogens, par
2011 11.400,00$

Reforms to the Pharmaceutical Benefits Scheme in Australia

Introduction / / As further statutory price cuts and “expanded and accelerated” price disclosure is applied to substitutable medi
2011 500,00$

Italy Pharmaceutical Market Overview Generic penetration set to rise

Introduction / / The prescription pharmaceutical market in Italy was valued at $24.9 billion in 2009. Key growth drivers for bran
2010 11.400,00$

Pipeline and Commercial Insight: Migraine - Challenges ahead for first-in-class developments

Introduction / / After 4 years of steady growth, the migraine market across the seven major regions was valued at $4.6 billion in
2010 15.200,00$

Pipeline Insight: Moderate-to-Severe Acute Pain - Positive outlook for opioid-sparing analgesics

Introduction / / The treatment of moderate to severe acute pain is dominated by opioids. While they offer excellent pain relief,
2010 15.200,00$

Stakeholder Insight: Gastric Cancer

Introduction / / Despite advances in surgery and the use of multimodality therapy, survival outcomes remain poor for gastric canc
2010 15.200,00$

Japan Pharmaceutical Market Overview Regulatory reforms will stimulate generics uptake

Introduction / / The pharmaceutical market in Japan was valued at $69.4 billion in 2009. Key growth drivers for branded pharma in
2010 11.400,00$

Pipeline and Commercial Insight: Alzheimer's Disease - Market cautiously awaits the first generation of disease-modifying therapies

Introduction / / Current management of Alzheimer’s disease is wholly inadequate, providing only symptomatic benefit to patients i
2010 15.200,00$

US Pharmaceutical Market Overview – Healthcare reform, economic pressures and the patent cliff set to impact Pharma

Introduction / / The US prescription pharmaceutical market was valued at $279 billion in 2009, with an annual growth rate of 5.5%
2010 11.400,00$

Stakeholder Opinions: Sexually Transmitted Diseases - An underestimated threat lacking interventions to prevent transmission

Introduction / / Sexually transmitted diseases (STDs) represent a significant health threat given their potentially serious compl
2010 3.800,00$

Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019

Introduction / / The oncology market has witnessed a sizeable shift of focus away from cytotoxic therapies and antihormonal thera
2010 15.200,00$

Brazil Pharmaceutical Market Overview – Expanding healthcare access drives double-digit sales growth

Introduction / / Brazil’s retail pharmaceutical market was valued at $12.6 billion in 2009, having grown by 14.3% between 2008 an
2010 7.600,00$

Pipeline and Commercial Insight: Moderate to Severe Chronic Nociceptive Pain - Anti-abuse opioids set to prosper

Introduction / / The moderate to severe chronic nociceptive pain market has boomed in the years since the removal of generic exte
2010 15.200,00$

Commercial Insight: Top 20 Cancer Therapy Brands

Introduction / / The top 20 cancer therapies achieved sales of over $30 billion in 2009 accounting for 75% of all cancer therapy
2010 15.200,00$

Commercial Insight: Antihormonal Cancer Therapies - Leading brands strive to minimize generic sales erosion

Introduction / / Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and pros
2010 15.200,00$

Stakeholder Opinions: Ovarian Cancer - Approaching the era of molecular targeted therapy

Introduction / / Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ov
2010 3.800,00$

Forecast Insight: Hepatitis B - Baraclude and Viread set to thrive in the face of limited competition

Introduction / / In 2009, hepatitis B sales across the seven major markets totalled $954m, demonstrating a CAGR of 37.5% between
2010 15.200,00$

Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive.

Introduction / / Datamonitor forecasts that the insulin antidiabetics market will grow from 10.6 billion in 2009 to $16.4 billion
2010 11.400,00$

Pipeline Insight: Lung Cancers Overview – Intensive R&D activity but little improvement in patient outcomes

Introduction / / Despite advances in therapy, prognosis for non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC)
2010 11.400,00$

Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitors bring added benefits to diabetes therapy.

Introduction / / Datamonitor forecasts the non-insulins antidiabetics market to grow to $18.8 billion in 2019 for the seven major
2010 11.400,00$

Pipeline and Commercial Insight: Urinary Incontinence - Marketing investment and niche positioning are key strategies for success

Introduction / / The urinary incontinence drug market has been displaying strong growth from 2005-09 owing to the uptake of new p
2010 15.200,00$

Abbott Laboratories: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sec
2010 5.700,00$

Prescription Pharmaceutical Market Sales Overview – Analysis of prescription pharmaceutical sales across 12 major markets

Introduction / / Prescription pharmaceutical sales in the world’s major markets (US, France, Germany, Italy, Spain, the UK, Japan
2010 15.200,00$

Bristol-Myers Squibb Co.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Bristol-Myers Squibb in the prescription phar
2010 5.700,00$

Brand Erosion Post-Patent Expiry – An analysis of small molecule brand erosion post-patent expiry

Introduction / / Pharma is facing slowing sales growth in the developed pharmaceutical markets, driven by increasing generic co
2010 15.200,00$

Pipeline and Commercial Insight: Neuropathic Pain - Pipeline setbacks prolong Pfizer's supremacy

Introduction / / At present, only six drugs are indicated for the treatment of neuropathic pain. In 2010, two significant event
2011 15.200,00$

Forecast Insight: Antibacterials

Introduction / / Over the next decade, the fragmented antibacterials market will shift away from a blockbuster-business model, as
2011 15.200,00$

Commercial Insight: Hepatitis B in China

Introduction / / Fuelled by the increasing use of new, expensive drugs, and the anticipated launch of new therapies, the Chinese
2011 5.700,00$

Pharmaceutical Key Trends 2011 - Brand Erosion Post-Patent Expiry

Introduction / / Pharma is facing slowing sales growth in the developed pharmaceutical markets, driven by increasing generic comp
2011 3.800,00$

Pharmaceutical Key Trends 2011 - Prescription Pharmaceutical Sales Overview

Introduction / / Prescription pharmaceutical sales in the world’s major markets (US, France, Germany, Italy, Spain, the UK, Japan
2011 3.800,00$

R&D Trends: Hepatitis C

Introduction / / Pegylated interferon in combination with ribavirin is the current standard of care for hepatitis C. While effect
2011 3.800,00$

R&D Trends: Allergic Rhinitis - Immunotherapy takes a rising share of the pipeline

Introduction / / The 2011 pipeline shows strong interest in immunotherapy, which makes up 42% of products in development. Advance
2011 3.800,00$

R&D Trends: Psoriasis - Pipeline outlook following withdrawal of key regulatory filing

Introduction / / Datamonitor identified 128 products in development, with a notable focus on interleukin (IL) targets. 2009 marke
2011 3.800,00$

Pharmaceutical Key Trends 2011 - Healthcare System and Drug Regulatory Overview: Cost-containment and regulatory pressures intensify

Introduction / / Healthcare expenditure is growing fast in all markets, driven by aging populations, a growing prevalence of chro
2011 3.800,00$

R&D Trends: HIV - An active pipeline faces fierce competition in the HIV market

Introduction / / Although there are a number of novel approaches in early-stage development for HIV, fierce competition is thinni
2011 3.800,00$

R&D Trends: Osteoporosis - Strong pipeline bodes well for future treatment

Introduction / / Over the last 12 months, there have been encouraging developments in the osteoporosis pipeline, with new therapi
2011 3.800,00$

Pipeline Insight: Cancer Overview- Breast and Gynecological Cancers - Promising agents emerge for BRCA positive patients

Introduction / The three tumor types covered in this report are set to account for just over 585,000 new cancer cases in 2010 with
2011 11.400,00$

Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina

Introduction / / Over the past decade, vaccines have resurfaced as an attractive commercial proposition for Pharma. The developed
2010 3.800,00$

Stakeholder Opinions: Cervical and Endometrial Cancer - Opportunities remain outside the big gynecologic malignancies

Introduction / / In cervical cancer, screening and human papillomavirus (HPV) vaccination have gradually shifted the focus toward
2010 3.800,00$

Stakeholder Opinions: Targeting Nerve Growth Factor for Pain Therapy - Groundbreaking class to breathe new life into saturated market

Introduction / / Pain treatment is a multibillion dollar market that is saturated with a wide variety of branded and generic drug
2010 3.800,00$

Commercial Insight: Top 20 Oncology Therapy Brands in Australia Revenues of targeted therapies soar while sales of cytotoxics and antihormonals decline

Introduction / / The Top 20 cancer therapy brands in Australia reached sales of about $545m in 2008, growing at a CAGR of 30% sin
2010 5.700,00$

Pipeline Insight: Gastrointestinal Cancer Overview - Metastatic gastrointestinal cancers represent a significant commercial opportunity due to a lack of approved drugs

Introduction / / The five tumor types covered in this report are set to account for nearly 898,000 new patients in 2010. Collecti
2010 11.400,00$

Pipeline Insight: Leukemias Underserved patient populations offer potential for market growth

Introduction / / Despite major advances in treatment in the last decade, a considerable percentage of the leukemia population sti
2010 11.400,00$

Stakeholder Opinions: Traumatic Brain Injury Hormonal therapy generates optimism

Introduction / / There remains no approved pharmacological or cellular treatment to improve the outcome of survivors of traumatic
2010 3.800,00$

Pipeline Insight: Lymphomas, Multiple Myeloma & Myelodysplastic Syndromes - Optimization of clinical practice creates opportunities for emerging therapies

Introduction / / The commercial success of Rituxan in the treatment of NHL and Velcade and Revlimid in the treatment of MM has at
2010 11.400,00$

Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth

Introduction / / Small molecule targeted therapies represent a highly lucrative class of anticancer therapies with 12 drugs curre
2010 11.400,00$

Commercial Insight: Opioids in Australia

Introduction / / The Australian opioid market grew from $63m in 2005 to $137m in 2009. Its growth will slow considerably and the
2010 5.700,00$

Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity

Introduction / / Faced with limited growth opportunities in western markets, HIV drug developers are looking to expand into emerg
2010 3.800,00$

Stakeholder Opinions: Melanoma Future treatment will be based on individual tumor gene expression signatures

Introduction / / The majority of patients present with early-stage melanoma, when surgery is often curative. Patients with metast
2010 3.800,00$

UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth

Introduction / / The UK prescription pharmaceutical market was valued at $28.4 billion in 2009. Key growth drivers include growin
2010 11.400,00$

Forecast Insight: HIV – Increasing dominance of fixed dose combinations raises bar for single agents

Introduction / / In 2009, HIV antiretroviral sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10
2010 15.200,00$

Stakeholder Opinions: Spinal Cord Injury - Attractive niche market with multi-billion dollar potential

Analysis of the patient potential of spinal cord injury across the seven major markets and rest of world.Review of key unmet clini
2010 3.800,00$

Pipeline Insight: Epilepsy - Past successes hard to emulate in highly genericized market

Analysis of current epilepsy treatments, unmet market needs and the impact of generics.Review of the late-stage epilepsy pipeline,
2010 11.400,00$

Forecast Insight: Depression - High rewards for novel and adjunctive therapies in treatment-resistant depression

Introduction / / Generic erosion, particularly in the US, will contribute to an overall depression market decline from $11.9bn in
2010 15.200,00$

Stakeholder Insight: Major Depressive Disorder - Gaining traction among physicians is crucial in an SSRI-dominated market

Introduction / / Prescribing trends reveal that the MDD market is receptive to alternative modes of actions at later lines of t
2010 15.200,00$

Asia-Pacific Healthcare Vertical Market Map 2010

Introduction / / The Healthcare Market Map is a comprehensive interactive model, which assesses and analyses the logistics indust
2011 10.000,00$

Global Top 10 Pharmaceutical Companies- Industry, Financial and SWOT Analysis

Datamonitor's Global Top 10 Pharmaceutical Companies report profiles the leading players in the pharmaceutical market worldwide. T
2011 1.895,00$

Americas Healthcare Vertical Market Map 2010

Introduction / / The Healthcare Market Map is a comprehensive interactive model, which assesses and analyses the logistics indust
2011 10.000,00$

Antibacterials: Market Forecast

Introduction / / Over the next decade, the fragmented antibacterials market will shift away from a blockbuster-business model, as
2011 15.200,00$

Australia Regional Wealth Markets Database 2010

Introduction / / While Australia was spared a recession, its wealthy suffered due to the global financial crisis. The first of it
2011 5.000,00$

BRIC Healthcare Vertical Market Map 2010

Introduction / / The Healthcare Market Map is a comprehensive interactive model, which assesses and analyses the logistics indust
2011 10.000,00$

Commercial Insight: Cardiovascular and Metabolic Market Forecast

Introduction / / Datamonitor expects antidiabetic therapies to emerge as the biggest revenue earner in the cardiovascular and met
2011 15.200,00$

Epidemiology: Cervical Cancer

Introduction / / Historical, and consequently future, incidence trends of cervical cancer are primarily related to access to and
2011 5.700,00$

Epidemiology: Hepatitis C

Introduction / / In 2010, Datamonitor estimates that there were about 6.9 million cases of hepatitis C virus in adults aged over
2011 5.700,00$

Epidemiology: Parkinson's Disease

Introduction / / In this report, Datamonitor has estimated that there were a total of 1.5 million cases of Parkinson’s disease
2011 5.700,00$

Epidemiology: Urinary Incontinence

Introduction / / In 2010, Datamonitor estimates that there will be about 83.4 million prevalent cases of urinary incontinence (UI
2011 5.700,00$

Neuropathic Pain Market Forecast

Introduction / / At present, only six drugs are indicated for the treatment of neuropathic pain. In 2010, two significant events
2011 15.200,00$

UAE Healthcare Vertical Market Map 2010

Introduction / / The Healthcare Market Map is a comprehensive interactive model, which assesses and analyses the logistics indust
2011 10.000,00$

OTC Healthcare in the Czech Republic to 2014

IntroductionThis databook provides key data and information on the OTC healthcare market in the Czech Republic. This report is a c
2011 495,00$

OTC Healthcare in Turkey to 2014

IntroductionThis databook provides key data and information on the OTC healthcare market in Turkey. This report is a comprehensive
2011 495,00$

Indigestion Preparations Market in Argentina to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Argentina (OTC Healthc
2011 350,00$

Indigestion Preparations Market in Asia-Pacific to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Asia-Pacific (OTC Heal
2011 350,00$

Indigestion Preparations Market in Austria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Austria (OTC Healthcar
2011 350,00$

Indigestion Preparations Market in Belgium to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Belgium (OTC Healthcar
2011 350,00$

Indigestion Preparations Market in Brazil to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Brazil (OTC Healthcare
2011 350,00$

Indigestion Preparations Market in Bulgaria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Bulgaria (OTC Healthca
2011 350,00$

Indigestion Preparations Market in China to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in China (OTC Healthcare)
2011 350,00$

Indigestion Preparations Market in Croatia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Croatia (OTC Healthcar
2011 350,00$

Indigestion Preparations Market in Eastern Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Eastern Europe (OTC He
2011 350,00$

Indigestion Preparations Market in Latin America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Latin America (OTC Hea
2011 350,00$

Indigestion Preparations Market in Middle East and Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Middle East and Africa
2011 350,00$

Indigestion Preparations Market in North America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in North America (OTC Hea
2011 350,00$

Indigestion Preparations Market in Western Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Western Europe (OTC He
2011 350,00$

Topical OTC Medicines Market in Israel to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Israel (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in Mexico to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Mexico (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in Nigeria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Nigeria (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in Pakistan to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Pakistan (OTC Healthcare)
2011 350,00$

Topical OTC Medicines Market in Romania to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Romania (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in Singapore to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Singapore (OTC Healthcare
2011 350,00$

Topical OTC Medicines Market in Slovenia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Slovenia (OTC Healthcare)
2011 350,00$

Indigestion Preparations Market in Denmark to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Denmark (OTC Healthcar
2011 350,00$

Indigestion Preparations Market in Egypt to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Egypt (OTC Healthcare)
2011 350,00$

Indigestion Preparations Market in Finland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Finland (OTC Healthcar
2011 350,00$

Indigestion Preparations Market in France to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in France (OTC Healthcare
2011 350,00$

Indigestion Preparations Market in Germany to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Germany (OTC Healthcar
2011 350,00$

Indigestion Preparations Market in Greece to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Greece (OTC Healthcare
2011 350,00$

Indigestion Preparations Market in Hong Kong to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Hong Kong (OTC Healthc
2011 350,00$

Indigestion Preparations Market in Hungary to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Hungary (OTC Healthcar
2011 350,00$

Indigestion Preparations Market in India to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in India (OTC Healthcare)
2011 350,00$

Indigestion Preparations Market in Indonesia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Indonesia (OTC Healthc
2011 350,00$

Indigestion Preparations Market in Ireland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Ireland (OTC Healthcar
2011 350,00$

Indigestion Preparations Market in Israel to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Israel (OTC Healthcare
2011 350,00$

Indigestion Preparations Market in Mexico to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Mexico (OTC Healthcare
2011 350,00$

Indigestion Preparations Market in the Netherlands to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in the Netherlands (OTC H
2011 350,00$

Indigestion Preparations Market in Nigeria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Nigeria (OTC Healthcar
2011 350,00$

Indigestion Preparations Market in Pakistan to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Pakistan (OTC Healthca
2011 350,00$

Indigestion Preparations Market in Romania to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Romania (OTC Healthcar
2011 350,00$

Indigestion Preparations Market in Singapore to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Singapore (OTC Healthc
2011 350,00$

Indigestion Preparations Market in Slovenia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Slovenia (OTC Healthca
2011 350,00$

Indigestion Preparations Market in South Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in South Africa (OTC Heal
2011 350,00$

Indigestion Preparations Market in South Korea to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in South Korea (OTC Healt
2011 350,00$

Indigestion Preparations Market in Spain to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Spain (OTC Healthcare)
2011 350,00$

Indigestion Preparations Market in Venezuela to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Venezuela (OTC Healthc
2011 350,00$

Indigestion Preparations Market in Vietnam to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Indigestion Preparations Market in Vietnam (OTC Healthcar
2011 350,00$

Medicated Skin Products Market in Asia-Pacific to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Asia-Pacific (OTC Healt
2011 350,00$

Medicated Skin Products Market in Eastern Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Eastern Europe (OTC Hea
2011 350,00$

Medicated Skin Products Market in Latin America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Latin America (OTC Heal
2011 350,00$

Medicated Skin Products Market in Middle East and Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Middle East and Africa
2011 350,00$

Medicated Skin Products Market in North America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in North America (OTC Heal
2011 350,00$

Medicated Skin Products Market in Western Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Western Europe (OTC Hea
2011 350,00$

Medicated Skin Products Market in Argentina to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Argentina (OTC Healthca
2011 350,00$

Medicated Skin Products Market in Austria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Austria (OTC Healthcare
2011 350,00$

Medicated Skin Products Market in Belgium to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Belgium (OTC Healthcare
2011 350,00$

Medicated Skin Products Market in Brazil to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Brazil (OTC Healthcare)
2011 350,00$

Medicated Skin Products Market in Bulgaria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Bulgaria (OTC Healthcar
2011 350,00$

Medicated Skin Products Market in China to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in China (OTC Healthcare).
2011 350,00$

Medicated Skin Products Market in Croatia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Croatia (OTC Healthcare
2011 350,00$

Medicated Skin Products Market in Denmark to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Denmark (OTC Healthcare
2011 350,00$

Medicated Skin Products Market in Egypt to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Egypt (OTC Healthcare).
2011 350,00$

Medicated Skin Products Market in Finland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Finland (OTC Healthcare
2011 350,00$

Medicated Skin Products Market in France to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in France (OTC Healthcare)
2011 350,00$

Medicated Skin Products Market in Germany to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Germany (OTC Healthcare
2011 350,00$

Medicated Skin Products Market in Greece to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Greece (OTC Healthcare)
2011 350,00$

Medicated Skin Products Market in Hong Kong to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Hong Kong (OTC Healthca
2011 350,00$

Medicated Skin Products Market in Hungary to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Hungary (OTC Healthcare
2011 350,00$

Medicated Skin Products Market in India to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in India (OTC Healthcare).
2011 350,00$

Medicated Skin Products Market in Indonesia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Indonesia (OTC Healthca
2011 350,00$

Medicated Skin Products Market in Ireland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Ireland (OTC Healthcare
2011 350,00$

Medicated Skin Products Market in Israel to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Israel (OTC Healthcare)
2011 350,00$

Medicated Skin Products Market in Mexico to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Mexico (OTC Healthcare)
2011 350,00$

Medicated Skin Products Market in the Netherlands to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in the Netherlands (OTC He
2011 350,00$

Medicated Skin Products Market in Nigeria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Nigeria (OTC Healthcare
2011 350,00$

Medicated Skin Products Market in Pakistan to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Pakistan (OTC Healthcar
2011 350,00$

Medicated Skin Products Market in Romania to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Romania (OTC Healthcare
2011 350,00$

Medicated Skin Products Market in Singapore to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Singapore (OTC Healthca
2011 350,00$

Medicated Skin Products Market in Slovenia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Slovenia (OTC Healthcar
2011 350,00$

Medicated Skin Products Market in South Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in South Africa (OTC Healt
2011 350,00$

Medicated Skin Products Market in South Korea to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in South Korea (OTC Health
2011 350,00$

Medicated Skin Products Market in Spain to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Spain (OTC Healthcare).
2011 350,00$

Medicated Skin Products Market in Venezuela to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Venezuela (OTC Healthca
2011 350,00$

Medicated Skin Products Market in Vietnam to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Medicated Skin Products Market in Vietnam (OTC Healthcare
2011 350,00$

Other OTC Healthcare Products Market in Asia-Pacific to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Asia-Pacific (OTC
2011 350,00$

Other OTC Healthcare Products Market in Eastern Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Eastern Europe (O
2011 350,00$

Other OTC Healthcare Products Market in Latin America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Latin America (OT
2011 350,00$

Other OTC Healthcare Products Market in Middle East and Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Middle East and A
2011 350,00$

Other OTC Healthcare Products Market in North America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in North America (OT
2011 350,00$

Other OTC Healthcare Products Market in Western Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Western Europe (O
2011 350,00$

Other OTC Healthcare Products Market in Argentina to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Argentina (OTC He
2011 350,00$

Other OTC Healthcare Products Market in Austria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Austria (OTC Heal
2011 350,00$

Other OTC Healthcare Products Market in Belgium to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Belgium (OTC Heal
2011 350,00$

Other OTC Healthcare Products Market in Brazil to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Brazil (OTC Healt
2011 350,00$

Other OTC Healthcare Products Market in Bulgaria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Bulgaria (OTC Hea
2011 350,00$

Other OTC Healthcare Products Market in China to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in China (OTC Health
2011 350,00$

Other OTC Healthcare Products Market in Croatia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Croatia (OTC Heal
2011 350,00$

Other OTC Healthcare Products Market in Denmark to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Denmark (OTC Heal
2011 350,00$

Other OTC Healthcare Products Market in Egypt to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Egypt (OTC Health
2011 350,00$

Other OTC Healthcare Products Market in Finland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Finland (OTC Heal
2011 350,00$

Other OTC Healthcare Products Market in France to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in France (OTC Healt
2011 350,00$

Other OTC Healthcare Products Market in Germany to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Germany (OTC Heal
2011 350,00$

Other OTC Healthcare Products Market in Greece to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Greece (OTC Healt
2011 350,00$

Other OTC Healthcare Products Market in Hong Kong to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Hong Kong (OTC He
2011 350,00$

Other OTC Healthcare Products Market in Hungary to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Hungary (OTC Heal
2011 350,00$

Other OTC Healthcare Products Market in India to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in India (OTC Health
2011 350,00$

Other OTC Healthcare Products Market in Indonesia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Indonesia (OTC He
2011 350,00$

Other OTC Healthcare Products Market in Ireland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Ireland (OTC Heal
2011 350,00$

Other OTC Healthcare Products Market in Israel to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Israel (OTC Healt
2011 350,00$

Other OTC Healthcare Products Market in Mexico to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Mexico (OTC Healt
2011 350,00$

Other OTC Healthcare Products Market in the Netherlands to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in the Netherlands (
2011 350,00$

Other OTC Healthcare Products Market in Nigeria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Nigeria (OTC Heal
2011 350,00$

Other OTC Healthcare Products Market in Pakistan to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Pakistan (OTC Hea
2011 350,00$

Other OTC Healthcare Products Market in Romania to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Romania (OTC Heal
2011 350,00$

Other OTC Healthcare Products Market in Singapore to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Singapore (OTC He
2011 350,00$

Other OTC Healthcare Products Market in Slovenia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Slovenia (OTC Hea
2011 350,00$

Other OTC Healthcare Products Market in South Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in South Africa (OTC
2011 350,00$

Other OTC Healthcare Products Market in South Korea to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in South Korea (OTC
2011 350,00$

Other OTC Healthcare Products Market in Spain to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Spain (OTC Health
2011 350,00$

Other OTC Healthcare Products Market in Venezuela to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Venezuela (OTC He
2011 350,00$

Other OTC Healthcare Products Market in Vietnam to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Other OTC Healthcare Products Market in Vietnam (OTC Heal
2011 350,00$

Plasters and Bandages Market in Asia-Pacific to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Asia-Pacific (OTC Healthc
2011 350,00$

Plasters and Bandages Market in Eastern Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Eastern Europe (OTC Healt
2011 350,00$

Plasters and Bandages Market in Latin America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Latin America (OTC Health
2011 350,00$

Plasters and Bandages Market in Middle East and Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Middle East and Africa (O
2011 350,00$

Plasters and Bandages Market in North America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in North America (OTC Health
2011 350,00$

Plasters and Bandages Market in Western Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Western Europe (OTC Healt
2011 350,00$

Plasters and Bandages Market in Argentina to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Argentina (OTC Healthcare
2011 350,00$

Plasters and Bandages Market in Austria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Austria (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in Belgium to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Belgium (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in Brazil to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Brazil (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in Bulgaria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Bulgaria (OTC Healthcare)
2011 350,00$

Plasters and Bandages Market in China to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in China (OTC Healthcare). T
2011 350,00$

Plasters and Bandages Market in Croatia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Croatia (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in Denmark to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Denmark (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in Egypt to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Egypt (OTC Healthcare). T
2011 350,00$

Plasters and Bandages Market in Finland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Finland (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in France to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in France (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in Germany to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Germany (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in Greece to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Greece (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in Hong Kong to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Hong Kong (OTC Healthcare
2011 350,00$

Plasters and Bandages Market in Hungary to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Hungary (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in India to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in India (OTC Healthcare). T
2011 350,00$

Plasters and Bandages Market in Indonesia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Indonesia (OTC Healthcare
2011 350,00$

Plasters and Bandages Market in Ireland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Ireland (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in Israel to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Israel (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in Mexico to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Mexico (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in the Netherlands to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in the Netherlands (OTC Heal
2011 350,00$

Plasters and Bandages Market in Nigeria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Nigeria (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in Pakistan to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Pakistan (OTC Healthcare)
2011 350,00$

Plasters and Bandages Market in Romania to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Romania (OTC Healthcare).
2011 350,00$

Plasters and Bandages Market in Singapore to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Singapore (OTC Healthcare
2011 350,00$

Plasters and Bandages Market in Slovenia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Slovenia (OTC Healthcare)
2011 350,00$

Plasters and Bandages Market in South Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in South Africa (OTC Healthc
2011 350,00$

Plasters and Bandages Market in South Korea to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in South Korea (OTC Healthca
2011 350,00$

Plasters and Bandages Market in Spain to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Spain (OTC Healthcare). T
2011 350,00$

Plasters and Bandages Market in Venezuela to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Venezuela (OTC Healthcare
2011 350,00$

Plasters and Bandages Market in Vietnam to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Plasters and Bandages Market in Vietnam (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in Asia-Pacific to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Asia-Pacific (OTC Healthc
2011 350,00$

Topical OTC Medicines Market in Eastern Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Eastern Europe (OTC Healt
2011 350,00$

Topical OTC Medicines Market in Latin America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Latin America (OTC Health
2011 350,00$

Topical OTC Medicines Market in Middle East and Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Middle East and Africa (O
2011 350,00$

Topical OTC Medicines Market in North America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in North America (OTC Health
2011 350,00$

Topical OTC Medicines Market in Western Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Western Europe (OTC Healt
2011 350,00$

Topical OTC Medicines Market in Argentina to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Argentina (OTC Healthcare
2011 350,00$

Topical OTC Medicines Market in Austria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Austria (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in Belgium to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Belgium (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in Brazil to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Brazil (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in Bulgaria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Bulgaria (OTC Healthcare)
2011 350,00$

Topical OTC Medicines Market in China to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in China (OTC Healthcare). T
2011 350,00$

Topical OTC Medicines Market in Croatia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Croatia (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in Denmark to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Denmark (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in Egypt to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Egypt (OTC Healthcare). T
2011 350,00$

Topical OTC Medicines Market in Finland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Finland (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in France to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in France (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in Germany to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Germany (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in Greece to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Greece (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in Hong Kong to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Hong Kong (OTC Healthcare
2011 350,00$

Topical OTC Medicines Market in Hungary to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Hungary (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in India to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in India (OTC Healthcare). T
2011 350,00$

Topical OTC Medicines Market in Indonesia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Indonesia (OTC Healthcare
2011 350,00$

Topical OTC Medicines Market in Ireland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Ireland (OTC Healthcare).
2011 350,00$

Topical OTC Medicines Market in the Netherlands to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in the Netherlands (OTC Heal
2011 350,00$

Topical OTC Medicines Market in South Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in South Africa (OTC Healthc
2011 350,00$

Topical OTC Medicines Market in South Korea to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in South Korea (OTC Healthca
2011 350,00$

Topical OTC Medicines Market in Spain to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Spain (OTC Healthcare). T
2011 350,00$

Topical OTC Medicines Market in Venezuela to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Venezuela (OTC Healthcare
2011 350,00$

Topical OTC Medicines Market in Vietnam to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Topical OTC Medicines Market in Vietnam (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in Asia-Pacific to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Asia-Pacific (OTC Healthc
2011 350,00$

Traditional Medicines Market in Eastern Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Eastern Europe (OTC Healt
2011 350,00$

Traditional Medicines Market in Latin America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Latin America (OTC Health
2011 350,00$

Traditional Medicines Market in Middle East and Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Middle East and Africa (O
2011 350,00$

Traditional Medicines Market in North America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in North America (OTC Health
2011 350,00$

Traditional Medicines Market in Western Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Western Europe (OTC Healt
2011 350,00$

Traditional Medicines Market in Argentina to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Argentina (OTC Healthcare
2011 350,00$

Traditional Medicines Market in Austria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Austria (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in Belgium to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Belgium (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in Brazil to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Brazil (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in Bulgaria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Bulgaria (OTC Healthcare)
2011 350,00$

Traditional Medicines Market in China to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in China (OTC Healthcare). T
2011 350,00$

Traditional Medicines Market in Croatia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Croatia (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in Denmark to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Denmark (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in Egypt to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Egypt (OTC Healthcare). T
2011 350,00$

Traditional Medicines Market in Finland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Finland (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in France to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in France (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in Germany to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Germany (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in Greece to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Greece (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in Hong Kong to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Hong Kong (OTC Healthcare
2011 350,00$

Traditional Medicines Market in Hungary to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Hungary (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in India to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in India (OTC Healthcare). T
2011 350,00$

Traditional Medicines Market in Indonesia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Indonesia (OTC Healthcare
2011 350,00$

Traditional Medicines Market in Ireland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Ireland (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in Israel to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Israel (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in Mexico to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Mexico (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in the Netherlands to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in the Netherlands (OTC Heal
2011 350,00$

Traditional Medicines Market in Nigeria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Nigeria (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in Pakistan to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Pakistan (OTC Healthcare)
2011 350,00$

Traditional Medicines Market in Romania to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Romania (OTC Healthcare).
2011 350,00$

Traditional Medicines Market in Singapore to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Singapore (OTC Healthcare
2011 350,00$

Traditional Medicines Market in Slovenia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Slovenia (OTC Healthcare)
2011 350,00$

Traditional Medicines Market in South Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in South Africa (OTC Healthc
2011 350,00$

Traditional Medicines Market in South Korea to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in South Korea (OTC Healthca
2011 350,00$

Traditional Medicines Market in Spain to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Spain (OTC Healthcare). T
2011 350,00$

Traditional Medicines Market in Venezuela to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Venezuela (OTC Healthcare
2011 350,00$

Traditional Medicines Market in Vietnam to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Traditional Medicines Market in Vietnam (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in Asia-Pacific to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Asia-Pacific (OTC Healthc
2011 350,00$

Vitamins and Minerals Market in Eastern Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Eastern Europe (OTC Healt
2011 350,00$

Vitamins and Minerals Market in Latin America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Latin America (OTC Health
2011 350,00$

Vitamins and Minerals Market in Middle East and Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Middle East and Africa (O
2011 350,00$

Vitamins and Minerals Market in North America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in North America (OTC Health
2011 350,00$

Vitamins and Minerals Market in Western Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Western Europe (OTC Healt
2011 350,00$

Vitamins and Minerals Market in Argentina to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Argentina (OTC Healthcare
2011 350,00$

Vitamins and Minerals Market in Austria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Austria (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in Belgium to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Belgium (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in Brazil to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Brazil (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in Bulgaria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Bulgaria (OTC Healthcare)
2011 350,00$

Vitamins and Minerals Market in China to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in China (OTC Healthcare). T
2011 350,00$

Vitamins and Minerals Market in Croatia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Croatia (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in Denmark to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Denmark (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in Egypt to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Egypt (OTC Healthcare). T
2011 350,00$

Vitamins and Minerals Market in Finland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Finland (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in France to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in France (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in Germany to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Germany (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in Greece to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Greece (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in Hong Kong to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Hong Kong (OTC Healthcare
2011 350,00$

Vitamins and Minerals Market in Hungary to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Hungary (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in India to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in India (OTC Healthcare). T
2011 350,00$

Vitamins and Minerals Market in Indonesia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Indonesia (OTC Healthcare
2011 350,00$

Vitamins and Minerals Market in Ireland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Ireland (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in Israel to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Israel (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in Mexico to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Mexico (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in the Netherlands to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in the Netherlands (OTC Heal
2011 350,00$

Vitamins and Minerals Market in Nigeria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Nigeria (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in Pakistan to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Pakistan (OTC Healthcare)
2011 350,00$

Vitamins and Minerals Market in Romania to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Romania (OTC Healthcare).
2011 350,00$

Vitamins and Minerals Market in Singapore to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Singapore (OTC Healthcare
2011 350,00$

Vitamins and Minerals Market in Slovenia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Slovenia (OTC Healthcare)
2011 350,00$

Vitamins and Minerals Market in South Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in South Africa (OTC Healthc
2011 350,00$

Vitamins and Minerals Market in South Korea to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in South Korea (OTC Healthca
2011 350,00$

Vitamins and Minerals Market in Spain to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Spain (OTC Healthcare). T
2011 350,00$

Vitamins and Minerals Market in Venezuela to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Venezuela (OTC Healthcare
2011 350,00$

Vitamins and Minerals Market in Vietnam to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Vitamins and Minerals Market in Vietnam (OTC Healthcare).
2011 350,00$

Analgesics Market in Asia-Pacific to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Asia-Pacific (OTC Healthcare). This
2011 350,00$

Analgesics Market in Eastern Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Eastern Europe (OTC Healthcare). Thi
2011 350,00$

Analgesics Market in Latin America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Latin America (OTC Healthcare). This
2011 350,00$

Analgesics Market in Middle East and Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Middle East and Africa (OTC Healthca
2011 350,00$

Analgesics Market in North America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in North America (OTC Healthcare). This
2011 350,00$

Analgesics Market in Western Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Western Europe (OTC Healthcare). Thi
2011 350,00$

Analgesics Market in Argentina to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Argentina (OTC Healthcare). This rep
2011 350,00$

Analgesics Market in Austria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Austria (OTC Healthcare). This repor
2011 350,00$

Analgesics Market in Belgium to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Belgium (OTC Healthcare). This repor
2011 350,00$

Analgesics Market in Brazil to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Brazil (OTC Healthcare). This report
2011 350,00$

Analgesics Market in Bulgaria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Bulgaria (OTC Healthcare). This repo
2011 350,00$

Analgesics Market in China to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in China (OTC Healthcare). This report
2011 350,00$

Analgesics Market in Croatia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Croatia (OTC Healthcare). This repor
2011 350,00$

Analgesics Market in Denmark to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Denmark (OTC Healthcare). This repor
2011 350,00$

Analgesics Market in Egypt to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Egypt (OTC Healthcare). This report
2011 350,00$

Analgesics Market in Finland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Finland (OTC Healthcare). This repor
2011 350,00$

Analgesics Market in France to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in France (OTC Healthcare). This report
2011 350,00$

Analgesics Market in Germany to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Germany (OTC Healthcare). This repor
2011 350,00$

Analgesics Market in Greece to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Greece (OTC Healthcare). This report
2011 350,00$

Analgesics Market in Hong Kong to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Hong Kong (OTC Healthcare). This rep
2011 350,00$

Analgesics Market in Hungary to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Hungary (OTC Healthcare). This repor
2011 350,00$

Analgesics Market in India to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in India (OTC Healthcare). This report
2011 350,00$

Analgesics Market in Indonesia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Indonesia (OTC Healthcare). This rep
2011 350,00$

Analgesics Market in Ireland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Ireland (OTC Healthcare). This repor
2011 350,00$

Analgesics Market in Israel to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Israel (OTC Healthcare). This report
2011 350,00$

Analgesics Market in Mexico to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Mexico (OTC Healthcare). This report
2011 350,00$

Analgesics Market in the Netherlands to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in the Netherlands (OTC Healthcare). Th
2011 350,00$

Analgesics Market in Nigeria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Nigeria (OTC Healthcare). This repor
2011 350,00$

Analgesics Market in Pakistan to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Pakistan (OTC Healthcare). This repo
2011 350,00$

Analgesics Market in Romania to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Romania (OTC Healthcare). This repor
2011 350,00$

Analgesics Market in Singapore to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Singapore (OTC Healthcare). This rep
2011 350,00$

Analgesics Market in Slovenia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Slovenia (OTC Healthcare). This repo
2011 350,00$

Analgesics Market in South Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in South Africa (OTC Healthcare). This
2011 350,00$

Analgesics Market in South Korea to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in South Korea (OTC Healthcare). This r
2011 350,00$

Analgesics Market in Spain to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Spain (OTC Healthcare). This report
2011 350,00$

Analgesics Market in Venezuela to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Venezuela (OTC Healthcare). This rep
2011 350,00$

Analgesics Market in Vietnam to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Analgesics Market in Vietnam (OTC Healthcare). This repor
2011 350,00$

Cough and Cold Preparations Market in Asia-Pacific to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Asia-Pacific (OTC H
2011 350,00$

Cough and Cold Preparations Market in Eastern Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Eastern Europe (OTC
2011 350,00$

Cough and Cold Preparations Market in Latin America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Latin America (OTC
2011 350,00$

Cough and Cold Preparations Market in Middle East and Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Middle East and Afr
2011 350,00$

Cough and Cold Preparations Market in North America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in North America (OTC
2011 350,00$

Cough and Cold Preparations Market in Western Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Western Europe (OTC
2011 350,00$

Cough and Cold Preparations Market in Argentina to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Argentina (OTC Heal
2011 350,00$

Cough and Cold Preparations Market in Austria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Austria (OTC Health
2011 350,00$

Cough and Cold Preparations Market in Belgium to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Belgium (OTC Health
2011 350,00$

Cough and Cold Preparations Market in Brazil to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Brazil (OTC Healthc
2011 350,00$

Cough and Cold Preparations Market in Bulgaria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Bulgaria (OTC Healt
2011 350,00$

Cough and Cold Preparations Market in China to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in China (OTC Healthca
2011 350,00$

Cough and Cold Preparations Market in Croatia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Croatia (OTC Health
2011 350,00$

Cough and Cold Preparations Market in Denmark to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Denmark (OTC Health
2011 350,00$

Cough and Cold Preparations Market in Egypt to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Egypt (OTC Healthca
2011 350,00$

Cough and Cold Preparations Market in Finland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Finland (OTC Health
2011 350,00$

Cough and Cold Preparations Market in France to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in France (OTC Healthc
2011 350,00$

Cough and Cold Preparations Market in Germany to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Germany (OTC Health
2011 350,00$

Cough and Cold Preparations Market in Greece to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Greece (OTC Healthc
2011 350,00$

Cough and Cold Preparations Market in Hong Kong to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Hong Kong (OTC Heal
2011 350,00$

Cough and Cold Preparations Market in Hungary to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Hungary (OTC Health
2011 350,00$

Cough and Cold Preparations Market in India to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in India (OTC Healthca
2011 350,00$

Cough and Cold Preparations Market in Indonesia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Indonesia (OTC Heal
2011 350,00$

Cough and Cold Preparations Market in Ireland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Ireland (OTC Health
2011 350,00$

Cough and Cold Preparations Market in Israel to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Israel (OTC Healthc
2011 350,00$

Cough and Cold Preparations Market in Mexico to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Mexico (OTC Healthc
2011 350,00$

Cough and Cold Preparations Market in the Netherlands to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in the Netherlands (OT
2011 350,00$

Cough and Cold Preparations Market in Nigeria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Nigeria (OTC Health
2011 350,00$

Cough and Cold Preparations Market in Pakistan to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Pakistan (OTC Healt
2011 350,00$

Cough and Cold Preparations Market in Romania to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Romania (OTC Health
2011 350,00$

Cough and Cold Preparations Market in Singapore to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Singapore (OTC Heal
2011 350,00$

Cough and Cold Preparations Market in Slovenia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Slovenia (OTC Healt
2011 350,00$

Cough and Cold Preparations Market in South Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in South Africa (OTC H
2011 350,00$

Cough and Cold Preparations Market in South Korea to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in South Korea (OTC He
2011 350,00$

Cough and Cold Preparations Market in Spain to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Spain (OTC Healthca
2011 350,00$

Cough and Cold Preparations Market in Venezuela to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Venezuela (OTC Heal
2011 350,00$

Cough and Cold Preparations Market in Vietnam to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the Cough and Cold Preparations Market in Vietnam (OTC Health
2011 350,00$

First Aid Kits Market in Asia-Pacific to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Asia-Pacific (OTC Healthcare). T
2011 350,00$

First Aid Kits Market in Eastern Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Eastern Europe (OTC Healthcare).
2011 350,00$

First Aid Kits Market in Latin America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Latin America (OTC Healthcare).
2011 350,00$

First Aid Kits Market in Middle East and Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Middle East and Africa (OTC Heal
2011 350,00$

First Aid Kits Market in North America to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in North America (OTC Healthcare).
2011 350,00$

First Aid Kits Market in Western Europe to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Western Europe (OTC Healthcare).
2011 350,00$

First Aid Kits Market in Argentina to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Argentina (OTC Healthcare). This
2011 350,00$

First Aid Kits Market in Austria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Austria (OTC Healthcare). This r
2011 350,00$

First Aid Kits Market in Belgium to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Belgium (OTC Healthcare). This r
2011 350,00$

First Aid Kits Market in Brazil to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Brazil (OTC Healthcare). This re
2011 350,00$

First Aid Kits Market in Bulgaria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Bulgaria (OTC Healthcare). This
2011 350,00$

First Aid Kits Market in China to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in China (OTC Healthcare). This rep
2011 350,00$

First Aid Kits Market in Croatia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Croatia (OTC Healthcare). This r
2011 350,00$

First Aid Kits Market in Denmark to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Denmark (OTC Healthcare). This r
2011 350,00$

First Aid Kits Market in Egypt to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Egypt (OTC Healthcare). This rep
2011 350,00$

First Aid Kits Market in Finland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Finland (OTC Healthcare). This r
2011 350,00$

First Aid Kits Market in France to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in France (OTC Healthcare). This re
2011 350,00$

First Aid Kits Market in Germany to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Germany (OTC Healthcare). This r
2011 350,00$

First Aid Kits Market in Greece to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Greece (OTC Healthcare). This re
2011 350,00$

First Aid Kits Market in Hong Kong to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Hong Kong (OTC Healthcare). This
2011 350,00$

First Aid Kits Market in Hungary to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Hungary (OTC Healthcare). This r
2011 350,00$

First Aid Kits Market in India to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in India (OTC Healthcare). This rep
2011 350,00$

First Aid Kits Market in Indonesia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Indonesia (OTC Healthcare). This
2011 350,00$

First Aid Kits Market in Ireland to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Ireland (OTC Healthcare). This r
2011 350,00$

First Aid Kits Market in Israel to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Israel (OTC Healthcare). This re
2011 350,00$

First Aid Kits Market in Mexico to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Mexico (OTC Healthcare). This re
2011 350,00$

Life Sciences Industry IT Spending Forecast in Argentina to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in Australia to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in Brazil to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in Canada to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in China to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in France to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in Germany to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in India to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in Italy to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in Japan to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in Mexico to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in Middle East and Africa to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in Russia to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in South Korea to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in Spain to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in the UK to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

Life Sciences Industry IT Spending Forecast in the US to 2015

IntroductionAs pharmaceutical and biotechnology companies increasingly turn to IT to reduce costs and the time-to-market of a drug
2010 995,00$

First Aid Kits Market in Nigeria to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Nigeria (OTC Healthcare). This r
2011 350,00$

First Aid Kits Market in Pakistan to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Pakistan (OTC Healthcare). This
2011 350,00$

First Aid Kits Market in Romania to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Romania (OTC Healthcare). This r
2011 350,00$

First Aid Kits Market in Singapore to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Singapore (OTC Healthcare). This
2011 350,00$

First Aid Kits Market in Slovenia to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Slovenia (OTC Healthcare). This
2011 350,00$

First Aid Kits Market in South Africa to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in South Africa (OTC Healthcare). T
2011 350,00$

First Aid Kits Market in South Korea to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in South Korea (OTC Healthcare). Th
2011 350,00$

First Aid Kits Market in Spain to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Spain (OTC Healthcare). This rep
2011 350,00$

First Aid Kits Market in the Netherlands to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in the Netherlands (OTC Healthcare)
2011 350,00$

First Aid Kits Market in Venezuela to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Venezuela (OTC Healthcare). This
2011 350,00$

First Aid Kits Market in Vietnam to 2014 (OTC Healthcare)

Introduction / / This databook provides key data and information on the First Aid Kits Market in Vietnam (OTC Healthcare). This r
2011 350,00$

Global Top 10 Pharmaceutical - Industry, Financial and SWOT Analysis

Datamonitor's Global Top 10 Pharmaceutical Companies report profiles the leading players in the pharmaceutical market worldwide. T
2011 1.895,00$

Allergic Rhinitis Market Forecast

Introduction / / Datamonitor estimates 2009 allergic rhinitis sales of $5 billion in the seven major markets, and forecasts a dec
2010 15.200,00$

Alzheimer's Disease Market Forecast

Introduction / / Current management of Alzheimer’s disease is wholly inadequate, providing only symptomatic benefit to patients i
2010 15.200,00$

Brief: Hepatitis C/AASLD 2010

Introduction / / Data from Phase III studies for Vertex/Johnson & Johnson’s telaprevir and Merck & Co’s boceprevir were the main
2010 500,00$

Parkinson's Disease Market Forecast

Introduction / / In 2009, the Parkinson’s disease market generated $2.2bn across the seven major markets. As the market approache
2010 15.200,00$

Pneumococcal and Meningococcal Vaccines: Market Forecast

Introduction / / Over the next decade, Pfizer’s Prevnar 13 is set to dominate the pneumococcal vaccine market with sales that cou
2010 15.200,00$

Psoriasis Market Forecast

Introduction / / In this report, Datamonitor assesses the main events which shaped the psoriasis market in the past five years, a
2010 15.200,00$

Rheumatoid Arthritis Market Forecast

Introduction / / In 2009, TNF inhibitors were the dominant drug class in terms of sales. However, there is growing use of non-TNF
2010 15.200,00$

Schizophrenia Market Forecast

Introduction / / Despite imminent generic erosion of blockbuster brands, the schizophrenia market will retain its value, supporte
2010 15.200,00$

Urinary Incontinence Market Forecast

Introduction / / The urinary incontinence drug market has been displaying strong growth from 2005-09 owing to the uptake of new p
2010 15.200,00$

Depression Market Forecast

Introduction / / Generic erosion, particularly in the US, will contribute to an overall depression market decline from $11.9bn in
2010 15.200,00$

Epidemiology: Alzheimer's Disease

Introduction / / An estimated 35.6 million people worldwide will be living with dementia in 2010. The number of patients with dem
2010 5.700,00$

Epidemiology: Breast Cancer

Introduction / Breast cancer will continue to be a major cancer among women in the seven major healthcare markets during the fore
2010 5.700,00$

Epidemiology: Depression

Introduction / / Depression is a very prevalent disease in the seven major markets (the US, Japan, France, Germany, Italy, Spain,
2010 5.700,00$

Epidemiology: Dyslipidemia

Introduction / / The large numbers of adults with dyslipidemia in the seven major markets countries can be directly attributed to
2010 5.700,00$

Epidemiology: Gastric Cancer

Introduction / / Since the 1950s, the incidence of gastric cancer has been declining in the seven major pharmaceutical markets (U
2010 5.700,00$

Epidemiology: Hepatocellular Cancer

Introduction / / Datamonitor estimates that 88,300 incident cases of hepatocellular cancer will occur in the seven major markets
2010 5.700,00$

Epidemiology: Ovarian Cancer

Introduction / / Incident cases of ovarian cancer will increase across the seven major healthcare markets between 2010 and 2019.
2010 5.700,00$

Epidemiology: Type 1 Diabetes

Introduction / / Due to an increasing incidence of type 1 diabetes in France, Germany, Italy, Spain, and the UK and a steady inci
2010 5.700,00$

Epidemiology: Type 2 Diabetes

Introduction / / Type 2 diabetes can be easily managed with a healthy lifestyle, especially related to diet, exercise, and weight
2010 5.700,00$

European Healthcare Vertical Market Map 2010

Introduction / / The Healthcare Market Map is a comprehensive interactive model, which assesses and analyses the logistics indust
2010 10.000,00$

Gilead Sciences: PharmaVitae Profile

Introduction / This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector
2010 5.700,00$

Takeda Pharmaceutical Co., Ltd: PharmaVitae Profile

Introduction / This analysis examines the historical and forecast performance for Takeda in the prescription pharmaceutical sector
2010 5.700,00$

Astellas Pharma Inc.: PharmaVitae Profile

Introduction / This analysis examines the historical and forecast performance for Astellas in the prescription pharmaceutical sect
2010 5.700,00$

Merck KGaA: PharmaVitae Profile

Introduction / This analysis examines the historical and forecast performance for Merck KGaA in the prescription pharmaceutical se
2010 5.700,00$

Biogen Idec Inc.: PharmaVitae Profile

Introduction / This analysis examines the historical and forecast performance for Biogen Idec in the prescription pharmaceutical s
2010 5.700,00$

Monoclonal Antibodies: 2010

Introduction / Across the branded prescription pharmaceutical market monoclonal antibodies (MAbs) are forecast to be the strongest
2010 7.600,00$

Generics Market Outlook: 2015

Introduction / Historical and forecast analysis of the entire generics industry from 2005 through to 2015. Strategic dynamics with
2010 7.600,00$

Stakeholder Insight: Breast Cancer (Hormone Receptor-Negative) - Triple-negative breast cancer offers a significant opportunity to new market entrants while Herceptin dominates the HER-2-positive market

Introduction / While some triple-negative breast cancer (TNBC) patients now have an additional treatment option in the form of Ava
2010 15.200,00$

OTC Healthcare in Asia Pacific - Product Launch Quarterly

Introduction / / Datamonitor’s OTC Healthcare in Asia Pacific – Product Launch Quarterly provides a complete guide to new product
2010 1.295,00$

OTC Healthcare in Eastern Europe - Product Launch Quarterly

Introduction / / Datamonitor’s OTC Healthcare in Eastern Europe – Product Launch Quarterly provides a complete guide to new produ
2010 1.295,00$

OTC Healthcare in Latin America - Product Launch Quarterly

Introduction / / Datamonitor’s OTC Healthcare in Latin America – Product Launch Quarterly provides a complete guide to new produc
2010 1.295,00$

OTC Healthcare in North America - Product Launch Quarterly

Introduction / / Datamonitor’s OTC Healthcare in North America – Product Launch Quarterly provides a complete guide to new produc
2010 1.295,00$

OTC Healthcare in Western Europe - Product Launch Quarterly

Introduction / / Datamonitor’s OTC Healthcare in Western Europe – Product Launch Quarterly provides a complete guide to new produ
2010 1.295,00$

Commercial Insight Top 20 cancer therapy brands forecast

Introduction / / The top 20 cancer therapies achieved sales of over $30 billion in 2009 accounting for 75% of all cancer therapy
2010 15.200,00$

Asthma/COPD Market Forecast

Introduction / / This model contains a 10 year country, indication, and device specific forecasts for individual products used in
2010 15.200,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Latvia

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Malaysia

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in New Zealand

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Nigeria

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Norway

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Pakistan

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Peru

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Poland

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Portugal

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Republic of Korea

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Romania

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Russia

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Saudi Arabia

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Singapore

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Slovakia

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Slovenia

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in South Africa

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Spain

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Sweden

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Switzerland

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Taiwan

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Thailand

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in the Netherlands

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in the Philippines

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in the US

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Turkey

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Ukraine

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in United Arab Emirates

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Uruguay

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Venezuela

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Vietnam

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2010 495,00$

Weight Management Trends & Behaviors: Beyond Dieting & Obesity

Detailed insights and analysis on the drivers and inhibitors of weight management. Includes strategic conclusions and actionable r
2010 3.450,00$

Global Top 10 Health Care Equipment Companies - Industry, Financial and SWOT Analysis

Global Top 10 Health Care Equipment Companies: Industry, Financial and SWOT Analysis / / Datamonitor's Global Top 10 Health Care
2010 1.895,00$

Hormone Replacement Therapy For Menopausal Symptoms Market Forecast

Introduction / / Sales of hormone replacement therapies treating menopausal symptoms have seen a sharp decline in recent years as
2010 15.200,00$

Testosterone Replacement Therapy Market Forecast

Introduction / / The testosterone replacement therapy market grew with an impressive compound annual growth rate [CAGR]: 24.3% fr
2010 15.200,00$

Antidiabetics market forecast

Introduction / / Datamonitor expects the antidiabetics market to grow to $34.8 billion in 2019 for the seven major markets. Januv
2010 15.400,00$

Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

Description of the competitive landscape in antidiabetics across seven major markets with market definition and overviewEvent-driv
2010 15.200,00$

Generics: Global Industry Guide

Datamonitor's Generics: Global Industry Guide is an essential resource for top-level data and analysis covering the Generics indus
2010 1.495,00$

Eli Lilly & Co.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Eli Lilly in the prescription pharma sector.
2010 5.700,00$

Johnson & Johnson: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The
2010 5.700,00$

AstraZeneca plc: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for AstraZeneca in the Rx pharmaceutical sector.
2010 5.700,00$

Amgen Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Amgen in the prescription pharmaceutical sect
2010 5.700,00$

Bayer Schering Pharma AG: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Bayer Schering in the prescription pharma se
2010 5.700,00$

F. Hoffmann-La Roche Ltd.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical sect
2010 5.700,00$

Genzyme Corporation: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical se
2010 5.700,00$

Merck & Co. Inc: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Merck & Co. in the Rx pharmaceutical sector.
2010 5.700,00$

Pfizer Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Pfizer in the prescription pharmaceutical sec
2010 5.700,00$

Sanofi-Aventis: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Sanofi-Aventis in the pharmaceutical sector.
2010 5.700,00$

OTC Healthcare in Belgium to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Belgium. This report is a compre
2009 495,00$

OTC Healthcare in Croatia to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Croatia. This report is a compre
2009 495,00$

OTC Healthcare in Nigeria to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Nigeria. This report is a compre
2009 495,00$

OTC Healthcare in Pakistan to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Pakistan. This report is a compr
2009 495,00$

OTC Healthcare in Saudi Arabia to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Saudi Arabia. This report is a c
2009 495,00$

Inflammatory Bowel Disease Market Forecast

Quantify the current size of IBD sales in the seven major markets and understand trends in the rest of the world / Understand IBD
2010 15.200,00$

Osteoporosis Market Forecast

Introduction / / Globally, the osteoporosis market displayed a 3.5% compound annual growth rate (CAGR) between 2005–09, reaching
2010 15.200,00$

Menarini: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Menarini in the prescription pharma sector. T
2010 5.700,00$

Merck KGaA: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Merck KGaA in the prescription pharma sector.
2010 5.700,00$

Actelion Ltd: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Actelion in the Rx pharmaceutical sector. Th
2010 5.700,00$

Nycomed S.C.A. SICAR: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Nycomed in the prescription pharmaceutical se
2010 5.700,00$

Sandoz International GmbH: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Sandoz in the prescription pharmaceutical sec
2010 5.700,00$

Forest Laboratories Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Forest in the prescription pharmaceutical sec
2010 5.700,00$

Biogen Idec Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Biogen Idec in the prescription pharma sector
2010 5.700,00$

Mylan Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Mylan in the prescription pharmaceutical sect
2010 5.700,00$

Celgene Corporation: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Celgene in the prescription pharmaceutical se
2010 5.700,00$

UCB S.A.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector
2010 5.700,00$

Shire plc: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sect
2010 5.700,00$

Cephalon Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Cephalon in the prescription pharma sector. T
2010 5.700,00$

Alcon Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Alcon in the prescription pharmaceutical sect
2010 5.700,00$

Watson Pharmaceuticals Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Watson in the prescription pharmaceutical sec
2010 5.700,00$

Benchmarking the Pharmaceutical Market by Drug Delivery to 2014

Assess how drug delivery has become an ever present feature in the business model of the leading pharmaceutical companiesProvides
2009 7.600,00$

Pet Health Care in Russia to 2013

Introduction / / This databook provides key data and information on the pet health care market in Russia. This report is a compre
2009 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Finland

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in France

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Germany

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Greece

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Hong Kong

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Hungary

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in India

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Indonesia

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Ireland

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Israel

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Italy

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Japan

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Lithuania

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Mexico

IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail dist
2010 495,00$

Top 10 Companies in Canada Healthcare Industry: IT Spending Predictor 2010

IntroductionThis databook provides estimates of IT spending for the top 10 companies in the Canadian Healthcare industry. The data
2010 795,00$

Top 10 Companies in Canada Life Sciences Industry: IT Spending Predictor 2010

IntroductionThis databook provides estimates of IT spending for the top 10 companies in the Canadian Life sciences industry. The d
2010 795,00$

Top 10 Companies in the US Healthcare Industry: IT Spending Predictor 2010

IntroductionThis databook provides estimates of IT spending for the top 10 companies in the US Healthcare industry. The databook i
2010 795,00$

Top 10 Companies in the US Life Sciences Industry: IT Spending Predictor 2010

IntroductionThis databook provides estimates of IT spending for the top 10 companies in the US Life sciences industry. The databoo
2010 795,00$

Cancer Targeted Therapies and Immunotherapies Market Forecast

IntroductionThe oncology market has witnessed a sizeable shift of focus away from cytotoxic therapies and antihormonal therapies t
2010 15.200,00$

Moderate to Severe Chronic Nociceptive Pain Market Forecast

IntroductionThe moderate to severe chronic nociceptive pain market has boomed in the years since the removal of generic extended-r
2010 15.200,00$

Antidyslipidemics Market Forecast

IntroductionThe antidyslipidemic market is approaching further genericization when in 2011, leading statin brand Lipitor will lose
2010 15.200,00$

Insomnia Market Forecast

IntroductionThe availability of generic versions of Ambien (zolpidem, Sanofi-Aventis) in the US from April 2007 onwards has intens
2010 15.200,00$

Industry Solutions Guide: Selecting an Ambulatory EHR Vendor in the Healthcare Market (Competitor Focus)

IntroductionThis report provides a comparative analysis of the leading ambulatory EHR vendors in the healthcare technology market
2010 3.395,00$

Antihormonal Therapies Market Forecast

Introduction Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prosta
2010 15.200,00$

Bristol-Myers Squibb Co.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for BMS in the prescription pharmaceutical sector
2010 5.700,00$

Health Care Equipment & Supplies: Global Industry Guide

Datamonitor's Health Care Equipment & Supplies: Global Industry Guide is an essential resource for top-level data and analysis cov
2010 1.495,00$

Daiichi Sankyo Co., Ltd: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Daiichi Sankyo in the Rx pharmaceutical secto
2010 5.700,00$

Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Takeda in the prescription pharmaceutical sec
2010 5.700,00$

Boehringer Ingelheim GmbH: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical
2010 5.700,00$

Genzyme Corporation: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical se
2010 5.700,00$

Mitsubishi Tanabe Pharma Corporation: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Mitsubishi Tanabe in the Rx drug sector. The
2010 5.700,00$

Multiple Sclerosis Market Forecast

Introduction / / With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladri
2010 15.200,00$

Eisai Co. Ltd: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Eisai in the prescription pharmaceutical sect
2010 5.700,00$

OTC Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry Guide

Datamonitor's OTC Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry Guid
2010 995,00$

Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry Guide

Datamonitor's Pharmaceuticals: Advanced Emerging Markets (Brazil, Hungary, Mexico, Poland, South Africa, Taiwan) Industry Guide is
2010 995,00$

Cytotoxic Therapies Market Forecast

Introduction / / Growth of cytotoxics will remain static over the forecast period with a CAGR of -0.1%. Several blockbuster produ
2010 15.200,00$

OTC Healthcare in Argentina to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Argentina. This report is a comp
2010 495,00$

OTC Healthcare in Austria to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Austria. This report is a compre
2010 495,00$

OTC Healthcare in Belgium to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Belgium. This report is a compre
2010 495,00$

OTC Healthcare in Brazil to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Brazil. This report is a compreh
2010 495,00$

OTC Healthcare in Bulgaria to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Bulgaria. This report is a compr
2010 495,00$

OTC Healthcare in China to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in China. This report is a comprehe
2010 495,00$

OTC Healthcare in Croatia to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Croatia. This report is a compre
2010 495,00$

OTC Healthcare in Denmark to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Denmark. This report is a compre
2010 495,00$

OTC Healthcare in Egypt to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Egypt. This report is a comprehe
2010 495,00$

OTC Healthcare in Finland to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Finland. This report is a compre
2010 495,00$

OTC Healthcare in France to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in France. This report is a compreh
2010 495,00$

OTC Healthcare in Germany to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Germany. This report is a compre
2010 495,00$

OTC Healthcare in Greece to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Greece. This report is a compreh
2010 495,00$

OTC Healthcare in Hong Kong to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Hong Kong. This report is a comp
2010 495,00$

OTC Healthcare in Hungary to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Hungary. This report is a compre
2010 495,00$

OTC Healthcare in India to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in India. This report is a comprehe
2010 495,00$

OTC Healthcare in Indonesia to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Indonesia. This report is a comp
2010 495,00$

OTC Healthcare in Ireland to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Ireland. This report is a compre
2010 495,00$

OTC Healthcare in Israel to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Israel. This report is a compreh
2010 495,00$

OTC Healthcare in Japan to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Japan. This report is a comprehe
2010 495,00$

OTC Healthcare in Malaysia to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Malaysia. This report is a compr
2010 495,00$

OTC Healthcare in Mexico to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Mexico. This report is a compreh
2010 495,00$

OTC Healthcare in Nigeria to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Nigeria. This report is a compre
2010 495,00$

OTC Healthcare in Pakistan to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Pakistan. This report is a compr
2010 495,00$

OTC Healthcare in Romania to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Romania. This report is a compre
2010 495,00$

OTC Healthcare in Saudi Arabia to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Saudi Arabia. This report is a c
2010 495,00$

OTC Healthcare in Singapore to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Singapore. This report is a comp
2010 495,00$

OTC Healthcare in Slovenia to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Slovenia. This report is a compr
2010 495,00$

OTC Healthcare in South Africa to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in South Africa. This report is a c
2010 495,00$

OTC Healthcare in South Korea to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in South Korea. This report is a co
2010 495,00$

OTC Healthcare in Spain to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Spain. This report is a comprehe
2010 495,00$

OTC Healthcare in Sweden to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Sweden. This report is a compreh
2010 495,00$

OTC Healthcare in Switzerland to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Switzerland. This report is a co
2010 495,00$

OTC Healthcare in Taiwan to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Taiwan. This report is a compreh
2010 495,00$

OTC Healthcare in Thailand to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Thailand. This report is a compr
2010 495,00$

OTC Healthcare in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014

Introduction / / This report covers key aspects of the ice cream market in four emerging / high growth economies: Brazil, Russia,
2010 1.995,00$

OTC Healthcare in the Netherlands to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in the Netherlands. This report is
2010 495,00$

OTC Healthcare in the Philippines to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in the Philippines. This report is
2010 495,00$

OTC Healthcare in the UK to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in the UK. This report is a compreh
2010 495,00$

OTC Healthcare in the US to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in the US. This report is a compreh
2010 495,00$

OTC Healthcare in United Arab Emirates to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in United Arab Emirates. This repor
2010 495,00$

OTC Healthcare in Uruguay to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Uruguay. This report is a compre
2010 495,00$

OTC Healthcare in Venezuela to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Venezuela. This report is a comp
2010 495,00$

OTC Healthcare in Vietnam to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market in Vietnam. This report is a compre
2010 495,00$

Other OTC Healthcare Products in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014

Introduction / / This report covers key aspects of the other OTC healthcare products market in four emerging / high growth econom
2010 1.995,00$

Topical OTC Medicines in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014

Introduction / / This report covers key aspects of the topical OTC medicines market in four emerging / high growth economies: Bra
2010 1.995,00$

Hepatitis B Market Forecast

Introduction / / This model contains a ten year commercial forecast of hepatitis B drug sales by country, class, molecule and bra
2010 15.200,00$

HIV Market Forecast

Introduction / / In 2009, HIV antiretroviral sales across the seven major markets totalled $11.8 billion, growing at a CAGR of 10
2010 15.200,00$

Migraine Market Forecast

Introduction / / After 4 years of steady growth, the migraine market across the seven major regions was valued at $4.6 billion in
2010 15.200,00$

Stakeholder Opinions: Sexually Transmitted Diseases - An underestimated threat lacking interventions to prevent transmission

Introduction / / Sexually transmitted diseases (STDs) represent a significant health threat given their potentially serious compl
2010 3.800,00$

Stakeholder Opinions: Ovarian Cancer - Approaching the era of molecular targeted therapy

Introduction / / Despite advances in the management of the disease, outcomes remain poor for patients with advanced epithelial ov
2010 3.800,00$

Analgesics in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014

Introduction / / This report covers key aspects of the analgesics market in four emerging / high growth economies: Brazil, Russia
2010 1.995,00$

Cough and Cold Preparations in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014

Introduction / / This report covers key aspects of the cough and cold preparations market in four emerging / high growth economie
2010 1.995,00$

First Aid Kits in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014

Introduction / / This report covers key aspects of the first aid kits market in four emerging / high growth economies: Brazil, Ru
2010 1.995,00$

Indigestion Preparations in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014

Introduction / / This report covers key aspects of the indigestion preparations market in four emerging / high growth economies:
2010 1.995,00$

Plasters & Bandages in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014

Introduction / / This report covers key aspects of the plasters & bandages market in four emerging / high growth economies: Brazi
2010 1.995,00$

Traditional Medicines in the BRIC (Brazil, Russia, India, China) Countries Ð Market Overview and Forecasts to 2014

Introduction / / This report covers key aspects of the traditional medicines market in four emerging / high growth economies: Bra
2010 1.995,00$

Global OTC Healthcare Market to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market covering 60 countries across the Gl
2010 495,00$

OTC Healthcare in Asia-Pacific to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market covering 15 countries in the Asia-P
2010 495,00$

OTC Healthcare in Eastern Europe to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market covering 11 countries in Eastern Eu
2010 495,00$

OTC Healthcare in Latin America to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market covering eight countries in Latin A
2010 495,00$

OTC Healthcare in Middle East and Africa to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market covering seven countries in the Mid
2010 495,00$

OTC Healthcare in North America to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market covering two countries in North Ame
2010 495,00$

OTC Healthcare in Western Europe to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market covering 17 countries in Western Eu
2010 495,00$

OTC Healthcare Market - Regional level to 2014

Introduction / / This databook provides key data and information on the OTC healthcare market for the following regions: Asia-Pac
2010 495,00$

Novartis AG: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Novartis in the prescription pharma sector. T
2010 5.700,00$

Global Top 10 Healthcare Equipment Companies - Industry, Financial and SWOT Analysis

Performance of the global healthcare equipment market on the basis of sales, volume and respective growth patterns over the past f
2010 1.895,00$

GlaxoSmithKline plc: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for GSK in the prescription pharmaceutical sector
2010 5.700,00$

Healthcare Providers Guide to Telehealth (Best Practice Insights)

Identifies the benefits telehealthDifferentiates between the types of telehealth technologiesProvides guidance on how to start a t
2010 1.895,00$

Opioids in Australia Market Forecast

Introduction / / The Australian opioid market grew from $63m in 2005 to $137m in 2009. Its growth will slow considerably and the
2010 5.700,00$

Global Top 10 Pharmaceutical Companies - Industry, Financial and SWOT Analysis

Performance of the global pharmaceutical market on the basis of sales, volume and respective growth patterns over the past five ye
2009 1.895,00$

OTC Healthcare in Latin America to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market covering eight countries in Latin A
2010 495,00$

Asthma/COPD in Australia Market Forecast

Introduction / / The Australian asthma/COPD market grew from $278m in 2006 to $333m in 2009. Its growth will slow considerably
2010 5.700,00$

Pharmaceutical Logistics Spending in Belgium to 2013

Introduction / / Pharmaceutical Logistics Spending in Belgium to 2013 provides a comprehensive analysis of the logistics spending
2010 995,00$

Pharmaceutical Logistics Spending in France to 2013

Introduction / / Pharmaceutical Logistics Spending in France to 2013 provides a comprehensive analysis of the logistics spending
2010 995,00$

Pharmaceutical Logistics Spending in Germany to 2013

Introduction / / Pharmaceutical Logistics Spending in Germany to 2013 provides a comprehensive analysis of the logistics spending
2010 995,00$

Pharmaceutical Logistics Spending in Italy to 2013

Introduction / / Pharmaceutical Logistics Spending in Italy to 2013 provides a comprehensive analysis of the logistics spending i
2010 995,00$

Pharmaceutical Logistics Spending in Spain to 2013

Introduction / / Pharmaceutical Logistics Spending in Spain to 2013 provides a comprehensive analysis of the logistics spending i
2010 995,00$

Pharmaceutical Logistics Spending in Sweden to 2013

Introduction / / Pharmaceutical Logistics Spending in Sweden to 2013 provides a comprehensive analysis of the logistics spending
2010 995,00$

Pharmaceutical Logistics Spending in the Netherlands to 2013

Introduction / / Pharmaceutical Logistics Spending in the Netherlands to 2013 provides a comprehensive analysis of the logistics
2010 995,00$

Pharmaceutical Logistics Spending in the UK to 2013

Introduction / / Pharmaceutical Logistics Spending in the UK to 2013 provides a comprehensive analysis of the logistics spending
2010 995,00$

Global Top 10 Biotechnology Companies Industry, Financial and SWOT Analysis

Performance of the global biotechnology market on the basis of sales, volume and respective growth patterns over the past five yea
2009 1.895,00$

Global Top 10 Chemical Companies Industry, Financial and SWOT Analysis

Performance of the global chemicals market on the basis of sales, volume and respective growth patterns over the past five yearsOb
2009 1.895,00$

Company Financials: Geron Corporation

IntroductionThe Company Financials offers insights into the financial performance of the company over last five years for about 10
2010 75,00$

Pharmaceuticals: Global Industry Overview

Datamonitor's Pharmaceuticals: Global Industry Overview is an essential resource for top-level data and analysis covering the Glob
2010 1.495,00$

Top 20 Cancer Therapy Brands in Australia Forecast

Introduction / / The Top 20 cancer therapy brands in Australia reached sales of about $545m in 2008, growing at a CAGR of 30% sin
2010 5.700,00$

Cloud Computing Adoption In The APAC Life Sciences Industry

Evaluates the responses of a total of 50 life sciences companies from India, China, and Japan.Discusses which types of companies a
2010 3.395,00$

2010 Guide to the Life Sciences Industry for Technology Providers

Offers an overview of the pharmaceutical and biotechnology sectorsDiscusses key areas where there is greatest need for technology
2010 1.895,00$

OTC Healthcare in Asia-Pacific to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market covering 15 countries in the Asia-P
2009 495,00$

OTC Healthcare in Australia to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Australia. This report is a comp
2009 495,00$

OTC Healthcare in Austria to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Austria. This report is a compre
2009 495,00$

OTC Healthcare in Brazil to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Brazil. This report is a compreh
2009 495,00$

OTC Healthcare in Canada to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Canada. This report is a compreh
2009 495,00$

OTC Healthcare in Chile to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Chile. This report is a comprehe
2009 495,00$

OTC Healthcare in China to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in China. This report is a comprehe
2009 495,00$

OTC Healthcare in Colombia to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Colombia. This report is a compr
2009 495,00$

OTC Healthcare in Denmark to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Denmark. This report is a compre
2009 495,00$

OTC Healthcare in Eastern Europe to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market covering 11 countries in Eastern Eu
2009 495,00$

OTC Healthcare in Egypt to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Egypt. This report is a comprehe
2009 495,00$

OTC Healthcare in Germany to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Germany. This report is a compre
2009 495,00$

OTC Healthcare in Greece to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Greece. This report is a compreh
2009 495,00$

OTC Healthcare in Hong Kong to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Hong Kong. This report is a comp
2009 495,00$

OTC Healthcare in Hungary to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Hungary. This report is a compre
2009 495,00$

OTC Healthcare in India to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in India. This report is a comprehe
2009 495,00$

OTC Healthcare in Indonesia to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Indonesia. This report is a comp
2009 495,00$

OTC Healthcare in Ireland to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Ireland. This report is a compre
2009 495,00$

OTC Healthcare in Italy to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Italy. This report is a comprehe
2009 495,00$

OTC Healthcare in Japan to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Japan. This report is a comprehe
2009 495,00$

OTC Healthcare in Mexico to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Mexico. This report is a compreh
2009 495,00$

OTC Healthcare in Morocco to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Morocco. This report is a compre
2009 495,00$

OTC Healthcare in New Zealand to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in New Zealand. This report is a co
2009 495,00$

OTC Healthcare in Portugal to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Portugal. This report is a compr
2009 495,00$

OTC Healthcare in Russia to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Russia. This report is a compreh
2009 495,00$

OTC Healthcare in Slovenia to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Slovenia. This report is a compr
2009 495,00$

OTC Healthcare in Sweden to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Sweden. This report is a compreh
2009 495,00$

OTC Healthcare in Switzerland to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Switzerland. This report is a co
2009 495,00$

OTC Healthcare in Taiwan to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Taiwan. This report is a compreh
2009 495,00$

OTC Healthcare in the Netherlands to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in the Netherlands. This report is
2009 495,00$

OTC Healthcare in the Philippines to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in the Philippines. This report is
2009 495,00$

OTC Healthcare in the UK to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in the UK. This report is a compreh
2009 495,00$

OTC Healthcare in the US to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in the US. This report is a compreh
2009 495,00$

OTC Healthcare in Turkey to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Turkey. This report is a compreh
2009 495,00$

OTC Healthcare in Ukraine to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Ukraine. This report is a compre
2009 495,00$

OTC Healthcare in Uruguay to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Uruguay. This report is a compre
2009 495,00$

OTC Healthcare in Vietnam to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Vietnam. This report is a compre
2009 495,00$

OTC Healthcare in Western Europe to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market covering 17 countries in Western Eu
2009 495,00$

OTC Healthcare Market - Regional level to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market for the following regions: Asia-Pac
2009 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Argentina

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis
2009 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Brazil

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis
2009 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Canada

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis
2009 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Chile

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis
2009 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Colombia

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis
2009 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Egypt

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis
2009 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Malaysia

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 retail dis
2009 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in Saudi Arabia

Introduction / / Datamonitor's retail databooks are based on key market value data for 8 major product sectors, 16 retail distrib
2009 495,00$

Drug Stores and Health and Beauty Stores (including Pharmacies) in United Arab Emirates

Introduction / / Datamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retai
2009 495,00$

OTC Healthcare in Finland to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Finland. This report is a compre
2009 495,00$

OTC Healthcare in France to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in France. This report is a compreh
2009 495,00$

OTC Healthcare in Malaysia to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Malaysia. This report is a compr
2009 495,00$

OTC Healthcare in North America to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market covering two countries in North Ame
2009 495,00$

OTC Healthcare in Norway to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Norway. This report is a compreh
2009 495,00$

OTC Healthcare in Poland to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Poland. This report is a compreh
2009 495,00$

OTC Healthcare in Singapore to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Singapore. This report is a comp
2009 495,00$

OTC Healthcare in South Africa to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in South Africa. This report is a c
2009 495,00$

OTC Healthcare in South Korea to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in South Korea. This report is a co
2009 495,00$

OTC Healthcare in Spain to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Spain. This report is a comprehe
2009 495,00$

OTC Healthcare in Thailand to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in Thailand. This report is a compr
2009 495,00$

OTC Healthcare in the Czech Republic to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in the Czech Republic. This report
2009 495,00$

OTC Healthcare in United Arab Emirates to 2013

Introduction / / This databook provides key data and information on the OTC healthcare market in United Arab Emirates. This repor
2009 495,00$

Pharmaceuticals: Asia-Pacific Industry Guide

Datamonitor's Pharmaceuticals: Asia-Pacific Industry Guide is an essential resource for top-level data and analysis covering the A
2010 995,00$

Pharmaceuticals: Belgium Industry Guide

Datamonitor's Pharmaceuticals: Belgium Industry Guide is an essential resource for top-level data and analysis covering the Belgiu
2010 995,00$

Pharmaceuticals: Canada Industry Guide

Datamonitor's Pharmaceuticals: Canada Industry Guide is an essential resource for top-level data and analysis covering the Canada
2010 995,00$

Pharmaceuticals: China Industry Guide

Datamonitor's Pharmaceuticals: China Industry Guide is an essential resource for top-level data and analysis covering the China Ph
2010 995,00$

Pharmaceuticals: Europe Industry Guide

Datamonitor's Pharmaceuticals: Europe Industry Guide is an essential resource for top-level data and analysis covering the Europe
2010 995,00$

Pharmaceuticals: France Industry Guide

Datamonitor's Pharmaceuticals: France Industry Guide is an essential resource for top-level data and analysis covering the France
2010 995,00$

Pharmaceuticals: Germany Industry Guide

Datamonitor's Pharmaceuticals: Germany Industry Guide is an essential resource for top-level data and analysis covering the German
2010 995,00$

Pharmaceuticals: Italy Industry Guide

Datamonitor's Pharmaceuticals: Italy Industry Guide is an essential resource for top-level data and analysis covering the Italy Ph
2010 995,00$

Pharmaceuticals: Japan Industry Guide

Datamonitor's Pharmaceuticals: Japan Industry Guide is an essential resource for top-level data and analysis covering the Japan Ph
2010 995,00$

Pharmaceuticals: Netherlands Industry Guide

Datamonitor's Pharmaceuticals: Netherlands Industry Guide is an essential resource for top-level data and analysis covering the Ne
2010 995,00$

Pharmaceuticals: Spain Industry Guide

Datamonitor's Pharmaceuticals: Spain Industry Guide is an essential resource for top-level data and analysis covering the Spain Ph
2010 995,00$

Pharmaceuticals: United Kingdom Industry Guide

Datamonitor's Pharmaceuticals: United Kingdom Industry Guide is an essential resource for top-level data and analysis covering the
2010 995,00$

Pharmaceuticals: United States Industry Guide

Datamonitor's Pharmaceuticals: United States Industry Guide is an essential resource for top-level data and analysis covering the
2010 995,00$

Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies

Forecast sales of the therapeutic cancer vaccines in late-phase development in the seven major markets over the period 2009 to 201
2009 11.400,00$

Stakeholder Insight: Osteoarthritis - Drug development lags behind rising osteoarthritis population

Snapshot of the osteoarthritis market based on a survey of 180 rheumatologists/primary care physicians, with views from key opinio
2009 15.200,00$

Neuropathic Pain Market Forecast

Introduction / / Datamonitor forecasts the neuropathic pain market to more than double in value from 2008 to total $5.2 billion b
2009 15.200,00$

Company Financials: Abbott Laboratories

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Acadia Pharmaceuticals Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Achillion Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Acorda Therapeutics, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Actelion Ltd

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Adolor Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: ADVENTRX Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Affymax, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Alcon, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Alexion Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Alexza Pharmaceuticals

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Alkermes, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Allos Therapeutics, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Alnylam Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Altus Pharmaceuticals Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Amgen, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Amylin Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Anadys Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Anesiva, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: AngioDynamics, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Antares Pharma, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Antisoma PLC

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: ARCA Biopharma, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Arena Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Arqule, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Array Biopharma Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Aryx Therapeutics, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: AspenBio Pharma

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: AstraZeneca PLC

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Auxilium Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Basilea Pharmaceutica

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Baxter International Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Beckman Coulter, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Becton, Dickinson and Company

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Biocryst Pharmaceuticals

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Biogen Idec, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: BioMarin Pharmaceutical Inc

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: BioMimetic Therapeutics, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: BIOMS Medicals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Biovail Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Boston Scientific Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Bristol-Myers Squibb Company

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: BTG plc

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: C. R. Bard, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Cadence Pharmaceuticals

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Candela Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Cardiome Pharma Corp

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Carl Ziess Meditec AG

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Celgene Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Celldex Therapeutics, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Cephalon, Inc

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Chelsea Therapeutics

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Cougar Biotechnology, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: CSL Limited

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Cubist Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: CuraGen Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Cypress Bioscience, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Cytokinetics, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Cytori Therapeutics Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Danaher Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Dendreon Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Depomed, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Discovery Laboratories, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: DURECT Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: DUSA Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Dyax Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Edwards Lifesciences Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Elan Corporation, plc

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Eli Lilly and Company

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Endo Pharmaceuticals Holdings Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Exelixis

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: F. Hoffmann-La Roche

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Flamel Technologies

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Forest Laboratories, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Gedeon Richter Plc

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Genentech, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Genmab A/S

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Genomic Health

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Genta Incorporated

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Genzyme Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Gilead Sciences, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: GlaxoSmithKline Plc

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: GTC Biotherapeutics, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: GTx, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Halozyme Therapeutics, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Hologic, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Human Genome Sciences, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Idenix Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Illumina, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: ImmunoGen, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Incyte

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Infinity Pharmaceuticals

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Inspire Pharmaceuticals

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: InterMune, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Intuitive Surgical

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Isis Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: ISTA Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Jazz Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Johnson & Johnson

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Keryx Biopharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Labopharm Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Life Technologies Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Mannkind Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Martek Biosciences Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Maxygen, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: MDRNA, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Medicis Pharmaceutical Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Medivation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Medtronic, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Merck & Co., Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Micromet

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Momenta Pharmaceuticals

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: MorphoSys AG

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Nektar Therapeutics

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Neurocrine Biosciences, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Novavax, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: NuVasive

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Oncogenex Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Optimer Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Orexigen Therapeutics, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: OSI Pharmaceuticals

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Pain Therapeutics, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Pfizer Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: POZEN, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Progenics Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Qiagen NV

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: QLT, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Recordati S.p.A.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Regeneron Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Salix Pharmaceuticals, Ltd.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Sangamo Biosciences, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Sanofi-Aventis SA

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Santarus, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Savient Pharmaceuticals Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Schering-Plough Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Seattle Genetics, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: SenoRx, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Shionogi & Co., Ltd.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Smith & Nephew plc

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Spectrum Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: St. Jude Medical, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Stryker Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: SuperGen, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Transcept Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: UCB S.A.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: United Therapeutics Corporation

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Varian Medical Systems, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Vertex Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: ViroPharma Incorporated

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Warner Chilcott Limited

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Watson Pharmaceuticals, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Wyeth

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Company Financials: Zimmer Holdings, Inc.

Introduction / / The Company Financials offers insights into the financial performance of the company over last five years for ab
2010 75,00$

Pet Health Care in India to 2013

Introduction / / This databook provides key data and information on the pet health care market in India. This report is a compreh
2010 495,00$

Pet Health Care in Latin America to 2013

Introduction / / This databook provides key data and information on the pet health care market covering eight countries in Latin
2010 495,00$

Pet Health Care in Asia-Pacific to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Australia to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Austria to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Belgium to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Canada to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Colombia to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Denmark to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Eastern Europe to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Egypt to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Finland to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in France to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Germany to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Greece to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Hungary to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Ireland to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Italy to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Japan to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Malaysia to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Middle East and Africa to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in New Zealand to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in North America to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Portugal to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in South Africa to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in South Korea to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Spain to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Sweden to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Switzerland to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Thailand to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in the Czech Republic to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in the Netherlands to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in the UK to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in the US to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care in Western Europe to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pet Health Care Market - Regional level to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Pharmaceutical IT Spending Forecast in Canada to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Canada through to 2013 / / *In each s
2009 995,00$

Pharmaceutical IT Spending Forecast in Mexico to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Mexico through to 2013 / / *In each s
2009 995,00$

Pharmaceutical IT Spending Forecast in the UK to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in the UK through to 2013 / / *In each s
2009 995,00$

Pharmaceutical IT Spending Forecast in the US to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in the US through to 2013 / / *In each s
2009 995,00$

Pharmaceutical IT Spending in Australia to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Australia through to 2013 / / *In eac
2009 995,00$

Pharmaceutical IT Spending in Brazil to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Brazil through to 2013 / / *In each s
2009 995,00$

Pharmaceutical IT Spending in China to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in China through to 2013 / / *In each su
2009 995,00$

Pharmaceutical IT Spending in France to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in France through to 2013 / / *In each s
2009 995,00$

Pharmaceutical IT Spending in Germany to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Germany through to 2013 / / *In each
2009 995,00$

Pharmaceutical IT Spending in India to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in India through to 2013 / / *In each su
2009 995,00$

Pharmaceutical IT Spending in Italy to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Italy through to 2013 / / *In each su
2009 995,00$

Pharmaceutical IT Spending in Japan to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Japan through to 2013 / / *In each su
2009 995,00$

Pharmaceutical IT Spending in South Korea to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in South Korea through to 2013 / / *In e
2009 995,00$

Pharmaceutical IT Spending in Spain to 2013

Scope / / *The databook provides forecasts relating to total pharmaceutical IT spending in Spain through to 2013 / / *In each su
2009 995,00$

Global Pet Health Care Market to 2013

Scope / / *Contains information on five categories: external parasite treatments, worming treatments, grooming products, pet supp
2009 495,00$

Orthopedics: Global Industry Guide

Datamonitor's Orthopedics: Global Industry Guide is an essential resource for top-level data and analysis covering the Orthopedics
2009 995,00$

Antibacterials Market Forecast

Introduction / / The antibacterials sector is increasingly shifting towards the hospital sector. In 2019, the fragmenting market
2009 15.200,00$

Antithrombotics Market Forecast

Introduction / / The antithrombotics market, comprising anticoagulant and antiplatelet sectors, has grown steadily over the 20040
2009 15.200,00$

Pharmaceutical Company Outlook to 2014

Introduction / / PharmaVitae universe Rx sales are forecast to expand at a 2008-14 CAGR of 1.2%, down 9.3 percentage points from
2009 7.600,00$

Stakeholder Insight: Cancer Pain - Physician survey highlights inadequacies in education and treatment

Introduction / / Estimated to affect 6.7 million individuals across the seven major markets in 2009, the population of patients s
2009 15.200,00$

Stakeholder Insight: Non-Hodgkin's Lymphomas Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)

Introduction / / The treatment outcomes for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients have impr
2009 15.200,00$

2009 Pharmaceutical M&A Overview

Introduction / / After a slump in M&A activity following the global economic downturn and with the looming threat of the 2011 "pa
2009 11.400,00$

Stakeholder Opinions: Therapeutic Vaccines - A far-off promise of greatness

Introduction / / The development of therapeutic vaccines has expanded beyond cancer indications and is attracting increasing inte
2009 3.800,00$

Stakeholder Opinions: Biomarkers in Rheumatology - Awaiting the next step towards personalized medicine

Introduction / / The growing recognition from companies of the applied benefits from biomarkers in rheumatology has spurred comme
2009 3.800,00$

Pipeline Insight: Endometriosis - New therapies near market while more innovative targets still needed

Introduction / / Endometriosis is a common yet poorly understood gynecological disease that affects women of reproductive age. Sy
2009 11.400,00$

Big Pharma Mega-Mergers 1995-2014

Introduction / / Mega-mergers (defined here as M&A events with deal sizes >$5bn) have been a long-term strategic feature of the p
2009 7.600,00$

Stakeholder Opinions: Gene Therapy - Gene therapy to deliver after 20 years of clinical development

Introduction / / Gene therapy looks to be coming of age, with seven projects in Phase III clinical development and one project cu
2009 3.800,00$

Boehringer Ingelheim GmbH: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical
2009 5.700,00$

Big Pharma Performance Before, During and Beyond the Global Recession

Introduction / / This report assesses the performance of the leading 15 pharmaceutical companies up to, during and beyond the rec
2009 7.600,00$

Supportive Care in Oncology Market Forecast

Introduction / / Supportive care in oncology is defined as those products used to prevent and/or treat the adverse side effects t
2009 15.200,00$

Mapping the Healthcare Landscape Bringing pharmaceuticals into focus

Introduction / / Courtesy of the patent cliff, the pharmaceutical industry is set for a dramatic slow down in revenue growth from
2009 7.600,00$

Monoclonal antibodies: 2009 update

Introduction / / The report provides a comprehensive financial and strategic analysis of the mAb market, forecasting its commerci
2009 7.600,00$

Emerging Markets Series: Indonesia and Philippines

Introduction / / As the developed markets are becoming increasingly mature, Pharma is turning to the emerging markets, where long
2009 7.600,00$

Antipsychotics Market Forecast

Introduction / / In 2008, seven major market sales of antipsychotics reached $18.2 billion. Datamonitor forecasts the market valu
2009 15.200,00$

Les Laboratoires Servier: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical se
2009 5.700,00$

King Pharmaceuticals Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for King in the prescription pharmaceutical secto
2009 5.700,00$

Pipeline Insight: Colorectal Cancer - Growing trend towards personalized medicine

Introduction / / CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will transl
2009 11.400,00$

Antidiabetics in Australia Market Forecast

Introduction / / Datamonitor expects the Australian antidiabetics market to reach $416m by 2018. The growth will be driven by the
2009 5.700,00$

Antihypertensives Market Forecast

Scope
2009 15.200,00$

Attention-Deficit Hyperactivity Disorder Market Forecast

Scope
2009 15.200,00$

Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact

Scope / / *Strategic analysis of the current influenza market across the US, Japan, France, Germany, Italy, Spain and the UK and
2009 15.200,00$

Forecast Insight: Antihypertensives New fixed dose combinations unable to stem the tide of patent expiries

Scope / / *Description of the competitive landscape in antihypertensives across seven major markets with market definition and ov
2009 15.200,00$

Inflammatory Bowel Disease Market Forecast

Scope
2009 15.200,00$

Molecular Targeted Cancer Therapies Market Forecast

Scope
2009 15.200,00$

New Multi-Marketing Channel Strategies

Scope / / *Provides an overview of the reasons behind the need for new marketing channels / / *Explores the different channel mi
2009 3.800,00$

Obesity Market Forecast

Scope
2009 15.200,00$

Osteoporosis Market Forecast

Scope
2009 15.200,00$

Pipeline and Commercial Insight: Osteoporosis - Novel agents to battle for payer acceptance

Scope / / * Patient potential analysis across the seven major markets and BRIC nations (Brazil, Russia, India, and China). /
2009 15.200,00$

Pricing and Reimbursement: Innovative Risk-Sharing Strategies

Scope / / *Overview of the different types of risk-sharing agreements adopted by manufacturers / / *Insight into the utilization
2009 3.800,00$

Psoriasis Market Forecast

Scope
2009 15.200,00$

Schering-Plough Corporation: PharmaVitae Profile

Scope
2009 5.700,00$

Seasonal Influenza Vaccines Market Forecast

Scope
2009 15.200,00$

Stakeholder Opinions: Skin and soft tissue infections

Scope / / *Epidemiological trends and economic impact of key pathogens / / *Overview of diagnosis and referral patterns / / *An
2009 3.800,00$

Wyeth: PharmaVitae Profile

Scope
2009 5.700,00$

Allergan Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Allergan in the Rx pharmaceutical sector. The
2009 5.700,00$

Anticonvulsants Market Forecast

Introduction / / In 2008, seven major market sales of anticonvulsants reached $13.6 billion, making it one of the largest therape
2009 15.200,00$

Antidepressants Market Forecast

Introduction / / With current blockbuster brands facing generic competition, Datamonitor forecasts the antidepressant market to d
2009 15.200,00$

Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sec
2009 5.700,00$

Gilead Sciences Inc.: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sec
2009 5.700,00$

Hormonal Contraceptives Market Forecast

Introduction / / Since the 1960s, hormonal contraceptives have been widely used as effective birth control in the developed world
2009 15.200,00$

Novo Nordisk A/S: PharmaVitae Profile

Introduction / / This analysis examines the historical and forecast performance for Novo Nordisk in the Rx pharmaceutical sector.
2009 5.700,00$

Orphan Drug Strategies

Introduction / / With the pharmaceutical industry reducing its focus on the primary care blockbuster model, Big Pharma is now loo
2009 3.800,00$

Parkinson's Disease Market Forecast

Introduction / / The Parkinson's disease market is approaching maturity, with the threat of generic incursion evident in each dru
2009 15.200,00$

Stakeholder Insight: Acute Leukemias - Reaching the limits of cytotoxic chemotherapy

Introduction / / The drug therapy of acute myeloid leukemia (AML) and adult acute lymphoblastic leukemia (ALL) is largely based o
2009 15.200,00$

Top 20 Cancer Therapy Brands Forecast

Introduction / / The cancer therapies market offers a high level of commercial reward to a handful of companies including Roche,
2009 15.200,00$

ProductTitle Healthcare Technology Spending Through 2014 (Interactive Model)

Understand the opportunity size for technology spending in the global healthcare market / Identify potential areas for spending
2009 15.000,00$

ProductTitle Future IT Trends and Projects: Healthcare Technology in India (Industry Focus)

Highlights future healthcare IT trends and opportunities / Analyzes the drivers and barriers of healthcare IT adoption / Outline
2009 1.895,00$

Celgene Corporation: PharmaVitae Profile

This analysis examines the historical and forecast performance for Celgene in the prescription pharmaceutical sector. The profile
2009 5.700,00$

Healthcare: Global Industry Guide

of the Report / / Contains an executive summary and data on value, volume and segmentation for Health Care Equipment, Health Ca
2009 555,00$

Johnson & Johnson: PharmaVitae Profile

This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encom
2009 5.700,00$

Opioids Market Forecast

The opioids market is set to grow from $9.6 billion in 2008 to $11.9 billion in 2018 across the seven major markets. However, the
2009 15.200,00$

Pharmaceuticals: Global Industry Guide

of the Report / / Contains an executive summary and data on value, volume and segmentation for Biotechnology, Generics, OTC Pha
2009 740,00$

Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos

Defining the key clinical characteristics of the pulmonary arterial sector that present a unique commercial challenge / / Transla
2009 3.800,00$

Stakeholder Opinions: Tuberculosis - Development pipeline shows signs of life

An overview of the epidemiological trends in the seven major markets and rest of world / / Discussion of the diagnostic methods f
2009 3.800,00$

Bayer Schering Pharma AG: PharmaVitae Profile

This analysis examines the historical and forecast performance for Bayer Schering Pharma in the ethical pharma sector. The profile
2009 5.700,00$

Biogen Idec Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Biogen Idec in the prescription pharma sector. The profile enco
2009 5.700,00$

Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile

This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile e
2009 5.700,00$

Dainippon Sumitomo Pharma Co. Ltd: PharmaVitae Profile

This analysis examines the historical and forecast performance for Dainippon Sumitomo in the Rx pharma sector. The profile encompa
2009 5.700,00$

F. Hoffmann-La Roche Ltd.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical sector. The profile en
2009 5.700,00$

Genentech Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Genentech in the Rx pharmaceutical sector. The profile encompas
2009 5.700,00$

GlaxoSmithKline plc: PharmaVitae Profile

This analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompass
2009 5.700,00$

King Pharmaceuticals Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for King in the prescription pharmaceutical sector. The profile enc
2009 5.700,00$

Les Laboratoires Servier: PharmaVitae Profile

This analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical sector. The profile
2009 5.700,00$

Merck & Co. Inc: PharmaVitae Profile

This analysis examines the historical and forecast performance for Merck & Co. in the Rx pharmaceutical sector. The profile en
2009 5.700,00$

Nicotine Dependence Market Forecast

With a considerable patient population and continued government focus on lowering national smoking rates, the nicotine dependence
2009 15.200,00$

Nycomed A/S: PharmaVitae Profile

This analysis examines the historical and forecast performance for Nycomed in the prescription pharmaceutical sector. The profile
2009 5.700,00$

Otsuka Pharmaceutical Group: PharmaVitae Model

This model contains historical and forecast sales data for Otsuka in the prescription pharmaceutical sector, based on company-repo
2009 5.700,00$

Otsuka Pharmaceutical Group: PharmaVitae Profile

This analysis examines the historical and forecast performance for Otsuka in the prescription pharmaceutical sector. The profile e
2009 5.700,00$

Pricing and Reimbursement in The United Arab Emirates

Overview of the healthcare reforms undertaken in Abu Dhabi and Dubai in order to contain costs / / Strategic analysis of the chan
2009 3.800,00$

Schering-Plough Corporation: PharmaVitae Profile

This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharma sector. The profile encom
2009 5.700,00$

Sepracor Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Sepracor in the prescription pharma sector. The profile encompa
2009 5.700,00$

Shire plc: PharmaVitae Profile

This analysis examines the historical and forecast performance for Shire in the ethical pharmaceutical sector. The profile encompa
2009 5.700,00$

Solvay S.A.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Solvay in the prescription pharmaceutical sector. The profile e
2009 5.700,00$

Stakeholder Opinions: Celiac Disease - Licensing opportunities exist in untapped market

Review of epidemiology, issues with diagnosisboth current techniques and those with future potentialand management of celiac disea
2009 3.800,00$

Stakeholder Opinions: Hematopoietic Stem Cell Transplantation - In need of further research and development

Usage data for HSCT and overview of the procedure in terms of stem cell donors, stem cell sources, and conditioning regimens / /
2009 3.800,00$

Stakeholder Opinions: Urinary Tract Infections Growing resistance rates bring opportunities for both new and old drugs

Disease background, segmentation and epidemiology of UTIs in the US, Japan and five major European countries / / Overview of unm
2009 3.800,00$

Stakeholder Opinions: Vaccine administration technologies - Beyond needles

In-depth analysis of key dermal and mucosal vaccine administration technologies / / Thorough assessment of the potential for sele
2009 3.800,00$

UCB S.A.: PharmaVitae Profile

This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile enco
2009 5.700,00$

Wyeth: PharmaVitae Profile

This analysis examines the historical and forecast performance for Wyeth in the prescription pharmaceutical sector. The profile en
2009 5.700,00$

Opportunities in Bone & Joint Health: Consumer Attitudes & Behaviors

Detailed insights and analysis documenting the drivers and inhibitors of bone and joint health enhancing food and beverages / / A
2009 3.995,00$

Opportunities in Heart Health: Consumer Attitudes & Behaviors

Detailed insights and analysis documenting the drivers and inhibitors of heart health enhancing products / / Analysis documenting
2009 3.995,00$

Pharmaceutical IT Spending in India to 2013

The databook provides forecasts relating to total pharmaceutical IT spending in India through to 2013 / In each sub-sector, pharm
2009 995,00$

Future Pharmaceutical Industry Trends:

Provides key strategies and trends shaping the future of the pharmaceutical industry / Examines the impact of the Obama administr
2009 5.700,00$

Hepatitis C - Therapy Area Pipeline Report

Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific ther
2009 1.495,00$

Hepatitis B - Therapy Area Pipeline Report

Understand a company’s strategic position by accessing detailed independent intelligence on its product pipeline for specific ther
2009 1.495,00$

Evaluating the Use of Superfruits as a Source of Antioxidants to Promote Health and Wellness

A conference presentation given by Datamonitor's New Consumer Insight (NCI) team in January 2009 / / This presentation combines c
2009 995,00$

PharmaVitae: Company Comparator Tool

The Comparator Tool builds from the PharmaVitae profiles of the 50 leading pharma companies. Updated monthly, the tool allows you
2009 45.600,00$

Pricing and Reimbursement in Key Asia Pacific Markets

Insight into pricing and reimbursement strategies in Australia, Singapore, China and Hong Kong / / Analysis of drivers and barrie
2009 3.800,00$

Pharmaceutical Company Outlook to 2013

Analysis of the sales outlook for the PharmaVitae universe of leading prescription pharma companies to 2013 / / Assessment of the
2008 7.600,00$

Stakeholder Opinions: Sarcomas

Overview of sarcoma subtypes, epidemiology, potential risk factors, disease staging and diagnosis / / Current treatment options f
2008 3.800,00$

Stakeholder Insight: Spondyloarthropathies - Disease perception limits market potential

Analysis of the results of a survey of 180 rheumatologists and 180 dermatologists supported by key opinion leader interviews / /
2008 15.200,00$

Biotech Financing in the Credit Crisis: Strategies for a radically altered landscape

Overview licensing trends up until the credit crisis / / Strategic analysis of biotech's funding crisis / / Insight into how the
2008 3.800,00$

Teva Pharmaceutical Industries Ltd: PharmaVitae Profile

This analysis examines the historical and forecast performance for Teva in the prescription pharmaceutical sector. The profile enc
2008 5.700,00$

Barr Pharmaceuticals Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Barr in the prescription pharmaceutical sector. The profile enc
2008 5.700,00$

Watson Pharmaceuticals Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Watson in the prescription pharmaceutical sector. The profile e
2008 5.700,00$

Mylan Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Mylan in the prescription pharmaceutical sector. The profile en
2008 5.700,00$

Cephalon Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Cephalon in the prescription pharma sector. The profile encompa
2008 5.700,00$

Commercial Insight: Rheumatoid arthritis - Anti-TNFs defend first-line biologic position despite competition

In-depth analysis of the current and future rheumatoid arthritis market across the US, 5EU and Japanese markets, and a 'rest of wo
2008 15.200,00$

Novartis AG: PharmaVitae Profile

This analysis examines the historical and forecast performance for Novartis in the prescription pharma sector. The profile encompa
2008 5.700,00$

Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas

Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor type
2008 11.400,00$

Stakeholder Opinions: Type 2 Diabetes in the UAE & Saudi Arabia Growth opportunities in fragmented markets

Description and analysis of the uniqueness of the antidiabetic markets in the UAE and Saudi Arabia / / Fragmented healthcare deli
2008 3.800,00$

Gilead Sciences Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector. The profile e
2008 5.700,00$

H. Lundbeck A/S: PharmaVitae Profile

This analysis examines the historical and forecast performance for Lundbeck in the prescription pharma global company strategy, po
2008 5.700,00$

Sandoz International GmbH: PharmaVitae Profile

This analysis examines the historical and forecast performance for Sandoz in the prescription pharmaceutical sector. The profile e
2008 5.700,00$

Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In times of crisis, Big Pharma turns to vaccines

Market overview with current market assessment in terms of leading players, brands and geographies / / In-depth analyses of the l
2008 15.200,00$

Stakeholder Insight: Infertility - Undifferentiated drugs force need to strengthen prescriber and payer relationship

Patient segmentation including detailed etiology of female and male infertility. / / Analysis of presentation, diagnosis, and tre
2008 15.200,00$

Sanofi-Aventis: PharmaVitae Profile

This analysis examines the historical and forecast performance for Sanofi-Aventis in the pharmaceutical sector. The profile encomp
2008 5.700,00$

Generics: Global Industry Guide

Contains an executive summary and data on value, volume and segmentation / / Provides textual analysis of the industry's prospe
2008 1.495,00$

Biotechnology: Global Industry Guide

Contains an executive summary and data on value, volume and segmentation / / Provides textual analysis of the industry's prospe
2008 1.495,00$

Orthopedics: Global Industry Guide

Contains an executive summary and data on value, volume and segmentation / / Provides textual analysis of the industry's prospe
2008 1.495,00$

Merck & Co. Inc: PharmaVitae Profile

This analysis examines the historical and forecast performance for Merck & Co. in the Rx pharmaceutical sector. The profile en
2008 5.700,00$

Forest Laboratories Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Forest in the prescription pharmaceutical sector. The profile e
2008 5.700,00$

King Pharmaceuticals Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for King in the prescription pharmaceutical sector. The profile enc
2008 5.700,00$

Stakeholder Insight: Chronic Leukemias - Is there room left for improvement?

Analysis of CLL and CML market based on a survey of 180 chronic leukemia specialists, supported by interviews carried out with key
2008 15.200,00$

Molecular Diagnostics: a primer on an emerging sector

A definitive classification system for in vitro diagnostics (IVD) and molecular diagnostics (MDx), and the differing regulatory pa
2008 7.600,00$

Shire plc: PharmaVitae Profile

This analysis examines the historical and forecast performance for Shire in the ethical pharmaceutical sector. The profile encompa
2008 5.700,00$

Stakeholder Insight: Systemic Lupus Erythematosus Imprecise segmentation complicates treatment algorithms

Analysis of key marketed brands and late-stage pipeline drugs. / / Anxiety disorders-specific drug sales volume and value forecas
2008 15.200,00$

Stakeholder Opinions: Bladder Cancer - New drugs needed to challenge ineffective 20-year old drugs

Current diagnosis and treatment of bladder cancer, including treatment regimens by stage and geographical location / / Issues in
2008 3.800,00$

Pet Health Care in Switzerland to 2011

Contains information on 5 categories: External Parasite Treatments, Grooming Products, Worming Treatments, Pet Supplements and Ot
2008 495,00$

Pet Health Care in the UK to 2011

Contains information on 5 categories: External Parasite Treatments, Grooming Products, Worming Treatments, Pet Supplements and Ot
2008 495,00$

Pet Health Care in Slovenia to 2011

Contains information on 5 categories: External Parasite Treatments, Grooming Products, Worming Treatments, Pet Supplements and Ot
2008 495,00$

Menarini: PharmaVitae Profile

This analysis examines the historical and forecast performance for Menarini in the prescription pharma sector. The profile encompa
2008 5.700,00$

Stakeholder Opinions: Diabetic Renal Disease

What are the current definitions, pathophysiological stages and the natural history of progression of diabetic renal disease? / /
2008 3.800,00$

RNA therapy: the next big thing after monoclonal antibodies?

Strategic review of the different RNA therapy technology offerings / / Assessment of the commercial potential of key products /
2008 7.600,00$

Sepracor Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Sepracor in the prescription pharma sector. The profile encompa
2008 5.700,00$

M&A trends in Pharma

Overview of the main trends driving M&A activity / / Analysis of key transactions in the past and the current state of the ne
2008 11.400,00$

Strategic Perspectives: Antidyslipidemics Current market is not conducive for growth

Description of the competitive landscape in antidyslipidemics market with detailed overview of main challenges for launched and no
2008 15.200,00$

Biogen Idec Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Biogen Idec in the prescription pharma sector. The profile enco
2008 5.700,00$

Solvay S.A.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Solvay in the prescription pharmaceutical sector. The profile e
2008 5.700,00$

Les Laboratoires Servier: PharmaVitae Profile

This analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical sector. The profile
2008 5.700,00$

Merck KGaA: PharmaVitae Profile

This analysis examines the historical and forecast performance for Merck KGaA in the prescription pharma sector. The profile encom
2008 5.700,00$

Stakeholder Insight: Osteoporosis - Generic alendronate further establishes oral bisphosphonates as gold standard

Patient segmentation by disease severity as defined by the WHO; including osteopenia, osteoporosis, and severe/established osteopo
2008 15.200,00$

Financial Deals Industry Tracker: Pharmaceuticals and Healthcare August 2008 (analysis of merger and acquisition (M&A), private equity, venture financing, private placement, initial public offering (IPO), and secondary offering deals)

Insights into deal activity across M&A, private equity, private placement, IPO, and secondary offering deals / In-depth anal
2008 495,00$

Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage

The antidyslipidemic market is expected to fall to $20 billion in 2017. The decline will be driven by the deep genericization of t
2008 15.200,00$

Sales Force Effectiveness

Provides an overview of the current drivers behind the evolution of sales force effectiveness / / Analyzes current and emerging s
2008 7.600,00$

Trends in Pharmaceutical Portfolio Management - Strategies to maintain profitability despite adversity

An overview of the current trends in pharmaceutical portfolio management / / Analysis of the ways in which pharmaceutical compani
2008 3.800,00$

Trends in Clinical Trials: Strategies to enhance clinical trial design

Overview of current clinical trial trends / / Strategic recommendations on how to optimize clinical trial success / / Case study
2008 3.800,00$

Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types

Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor type
2008 11.400,00$

F. Hoffmann-La Roche Ltd.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical sector. The profile en
2008 5.700,00$

Nycomed A/S: PharmaVitae Profile

This analysis examines the historical and forecast performance for Nycomed in the prescription pharmaceutical sector. The profile
2008 5.700,00$

Genzyme Corporation: PharmaVitae Profile

This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile
2008 5.700,00$

Viropharma Incorporated: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysis,
2008 495,00$

Cubist Pharmaceuticals Inc: Strategic Corporate Assessment - Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysis,
2008 495,00$

Big Pharma M&A Analysis to 2012 - Surveying the growth rate landscape

Company-by-company evaluation of all Big Pharma-led M&A permutations within the PharmaVitae Rx pharma universe / / Evaluation of
2008 7.600,00$

GlaxoSmithKline plc: PharmaVitae Profile

This analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompass
2008 5.700,00$

Eli Lilly & Co.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Eli Lilly in the Rx pharmaceutical sector. The profile encompas
2008 5.700,00$

Boehringer Ingelheim GmbH: PharmaVitae Profile

This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profi
2008 5.700,00$

Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile

This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile e
2008 5.700,00$

Genentech Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Genentech in the Rx pharmaceutical sector. The profile encompas
2008 5.700,00$

Financial Deals Industry Tracker: Pharmaceuticals and Healthcare June 2008 (analysis of monthly deal activity along with the trend for the last six months for merger and acquisition (M&A), private equity, venture financing, private placement, initial publ

Insights into deal activity across M&A, private equity, private placement, IPO, and secondary offering deals / In-depth analysis
2008 495,00$

Bristol-Myers Squibb Co.: PharmaVitae Profile

This analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompass
2008 5.700,00$

Novo Nordisk A/S: PharmaVitae Profile

This analysis examines the historical and forecast performance for Novo Nordisk in the ethical pharmaceutical sector. The profile
2008 5.700,00$

Stakeholder Opinions: Diagnostics in Neurology - Predictive biomarkers expand drug revenues

Neurological conditions covered: Alzheimer's disease, Parkinson's disease, MS, epilepsy, migraine, insomnia, Huntington's disease
2008 3.800,00$

Schering-Plough Corporation: PharmaVitae Profile

This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharma sector. The profile encom
2008 5.700,00$

Stakeholder Opinions: Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of market prospects for biologics expose an opportunity for cell and gene therapies

Analysis of the current unmet needs in cardiovascular disease markets / / Opinion leader commentary on key clinical trials and ma
2008 7.600,00$

Commercial and Pipeline Insight: Vaccines for Adults and the Elderly - New blockbuster opportunities ahead

Assessment of pneumococcal and zoster disease incidence, in-depth analysis of existing vaccines and key pipeline compounds / / R
2008 15.200,00$

Johnson & Johnson: PharmaVitae Profile

This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompass
2008 5.700,00$

Wyeth: PharmaVitae Profile

This analysis examines the historical and forecast performance for Wyeth in the prescription pharmaceutical sector. The profile en
2008 5.700,00$

Bayer Schering Pharma AG: PharmaVitae Profile

This analysis examines the historical and forecast performance for Bayer Schering Pharma in the ethical pharma sector. The profile
2008 5.700,00$

Financial Deals Industry Tracker: Pharmaceuticals and Healthcare (analysis of monthly deal activity, along with the trend for the last six months for merger and acquisition (M&A), private equity, venture financing, private placement, initial public offeri

Insights into deal activity across M&A, private equity, private placement, IPO, and secondary offering deals / In-depth analysis
2008 495,00$

Zimmer Holdings Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Varian Medical Systems Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

CSL Limited: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Micromet Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Optimer Pharmaceuticals Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Javelin Pharmaceuticals Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Spectrum Pharmaceuticals Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Nuvelo Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Incyte Corporation: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Stryker Corporation: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Panacos Pharmaceuticals Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

La Jolla Pharmaceutical Co: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Lexicon Pharmaceuticals Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

KV Pharmaceutical Company: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Avigen Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

C.R. Bard Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Danaher Corporation: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Medtronic Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Smith & Nephew plc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Transition Therapeutics Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

TorreyPines Therapeutics Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

St. Jude Medical Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Novacea Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Illumina Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

LifeCell Corporation: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

MannKind Corporation: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Cytori Therapeutics Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Cougar Biotechnology Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

MorphoSys AG: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Lev Pharmaceuticals Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Introgen Therapeutics Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Theratechnologies Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Poniard Pharmaceuticals Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Becton, Dickinson and Co: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Allos Therapeutics Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Antisoma plc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Beckman Coulter Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

BIOMS Medical Corp: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Anesiva Inc: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Boston Scientific Corporation: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

Carl Zeiss Meditec AG: Premium Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-ye
2008 495,00$

ZIOPHARM Oncology Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysis,
2008 495,00$

Watson Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Vital Signs Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Vernalis plc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Trinity Biotech Plc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

TomoTherapy Incorporated: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Titan Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

The Medicines Company: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Telik Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Targanta Therapeutics Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

SenoRx Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Sangamo BioSciences Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Qiagen NV: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Protherics PLC: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Orexigen Therapeutics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

NuVasive Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Noven Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Natus Medical Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Metabasis Therapeutics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Medivation Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Jazz Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Iomai Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Intuitive Surgical Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Hologic Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Halozyme Therapeutics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Geron Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Genomic Health Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Genaera Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Flamel Technologies SA: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Favrille Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Edwards Lifesciences Corp: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Dendreon Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Chelsea Therapeutics International Ltd: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Candela Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Cadence Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

BTG plc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Biovail Corporation: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Bionovo Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

BioMimetic Therapeutics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Basilea Pharmaceutica: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

AVANT Immunotherapeutics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

AspenBio Pharma Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

ARYx Therapeutics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

AngioDynamics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Anadys Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

ADVENTRX Pharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Advanced Medical Optics Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Accentia Biopharmaceuticals Inc: Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis and 5-year Adjusted Financials with In-depth Company Profile

Contains corporate strategy, value chain presence and SWOT Analysis / / Provides detailed business description, segment analysi
2008 495,00$

Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand

Overview of menopause, including a review of the prevalence of vasomotor symptoms to better understand the size of the target pati
2008 3.800,00$

Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players

Analysis of patient potential, unmet needs and clinical trial design in the neuropathic pain market. / / Overview of key marketed
2008 15.200,00$

Monoclonal Antibodies Report: 2008 Update

Comprehensive financial strategic analysis of the mAb market out to 2013 / / Global sales forecasts to 2013 for marketed and Phas
2008 7.600,00$

Online patient recruitment and its impact on patient relationship management

Overview of the benefits and drawbacks of online recruitment Analysis of the online patient recruitment process Analysis of the ke
2008 3.800,00$

Forecast Insight: Osteoarthritis -

Scope / / This report gives a strategic analysis of the likely impact that recent events will have on the osteoarthritis market
2008 15.200,00$

Drug Repositioning Strategies - Serendipity by design

Scope / An outline of what drug repositioning is, and what is driving it. / / An overview of the key players in the repositioning
2008 3.800,00$

Stakeholder Opinions: Biologics in Infectious Diseases Well defined target populations are key to commercial success

An overview of the past, current and emerging technologies for biologics as well as obstacles faced in development. Discussion of
2008 3.800,00$

Pharmaceutical Supply chain strategies: Reassessing product distribution to cut costs and improve supply chain management

An overview of the drug supply chain in Europe and the US. Identification of the key players in the drug supply chain. Coverage of
2008 3.800,00$

Stakeholder Opinions: Systemic Lupus Erythematosus - Market set to enter era of biologic therapies

Assessment of patient size across the seven major and additional emerging markets, including split by sex and race where available
2008 3.800,00$

Stakeholder Opinions: Bone Metastases - Impending patent expiries may help make or break newer agents

Overview of bone metastases epidemiology, which is currently unknown, disease mechanisms, complications and diagnosis Current trea
2008 3.800,00$

eHealthInsight Series: Reaching Doctors and Patients Through New Digital Media

Overview of the current challenges facing existing sales and marketing models. A review of online activities of physicians and pat
2008 3.800,00$

Using a Multi-faceted Approach to Increasing EHR Adoption (Strategy Focus)

Identifies opportunities in the global EHR market Analyzes approaches to EHR adoption Offers insight into EHR technology trends /
2008 1.895,00$

Wealth Management in Japan 2007

Presents data from Datamonitor's Global Wealth model on the number of wealthy individuals and their aggregate onshore liquid asset
2007 4.495,00$

Wealth Management in Australia 2007

Presents data from Datamonitor's Global Wealth model on the number of wealthy individuals and their aggregate onshore liquid asset
2007 4.495,00$

Formulating an effective CRM strategy (Strategy Focus)

Pharmaceutical companies need to increase drugs' profitability during its profit window A reduced sales force needs to be more
2007 1.895,00$

M&A, Partnerships and Organic Growth in Wealth Management, Q2 2007

Extensive research is conducted on the activities of 50 providers of wealth management products, globally The developments are ana
2007 1.695,00$

Product Innovation and Customer Targeting in Wealth Management, Q2 2007

Extensive research is conducted on the activities of 50 providers of wealth management products, globally The developments are ana
2007 1.695,00$

Staffing in Wealth Management, Q2 2007

Follows the staffing-related activities of 57 leading international wealth managers Covers wealth managers with operations worldwi
2007 1.695,00$

Future Spending of CRM Technologies, Europe, 2006-2012 (Databook)

Includes segmentations for software and services in the CRM market for the Pharmaceutical industry. Projects the growth for the ma
2007 1.295,00$

Future Spending of CRM Technologies, North America and Japan, 2006-2012 (Databook)

Includes segmentations for software and services in the CRM market for the Pharmaceutical industry. Projects the growth for the ma
2007 1.895,00$

Global Pharmaceutical IT Spending Forecast through 2013 (Interactive Model)

Understand the opportunity size for technology spending in the global life science market / Identify potential areas for spending
2008 15.000,00$

markt-studie.de ist ein unabhängiges Verkaufsportal für Marktstudien, Marktanalysen und Marktforschung. Unser Angebot umfasst weit über 240.000 Studien mit aktuellen Marktdaten (Marktinformationen, Marktpotentiale, Marktentwicklung, etc.) für Tausende Segmente deutschland-, europa- und weltweit. Alle Markt-Studien und Branchenreports können bequem online oder per Fax bestellt werden.


markt-studie.de : Markt studien datamonitor pharma gesundheit